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ABSTRACT 
ORGANIZATIONAL CORRELATES OF MEDICATION-ASSISTED TREATMENT 
(MAT) IN SUBSTANCE ABUSE TREATMENT FACILITIES: EXAMINING HOW 
INSTITUTIONAL FORCES SHAPE TREATMENT 
Maayan Lawental Schori 
Toorjo Ghose 
 Methadone and buprenorphine/naloxone are the two recommended 
pharmacotherapies for the treatment of opioid dependence, having been demonstrated to 
be effective in numerous clinical trials. While methadone has been an approved treatment 
for opioid dependence for that past 50 years, buprenorphine/naloxone is a newer 
substance that was only approved for use in 2002. This mixed-methods study utilizes a 
comprehensive conceptual framework of neoinstitutional theory and institutional logics 
to explore possible factors that might predict adoption of medication-assisted treatment.  
 First, in-depth qualitative interviews with managerial level staff at substance 
abuse treatment centers were conducted. The interviews were semi-structured and 
explored perceptions of treatment philosophy, the merging of substance abuse and mental 
health, managed care, services, funding, licensing and accreditation and personal and 
professional networks. Next, logistic regression models were used to explore possible 
predictors of medication-assisted treatment. The National Treatment Center Study 
(NTCS), a nationally representative survey of private substance abuse treatment facilities 
conducted between 2002-2004, was used in this study, allowing for the exploration of 
early adoption of buprenorphine/naloxone. 
 Findings from the qualitative interviews suggested that the two medications are 
viewed differently and should therefore be explored separately. Findings from the logistic 
analysis of the NTCS supported this distinction. The proportion of clients with a primary 
diagnosis of opiate dependence or abuse was the only factor positively associated with 
both the early adoption of buprenorphine/naloxone and methadone provision. The 
program’s proportion of managed care funding was the only other significant predictor 
for early adoption of buprenorphine/naloxone. Accreditation by JACHO, proportion of 
clients who are women and past organizational participation in research, all positively 
predicted methadone provision, while the proportion of counselors with a master’s degree 
or higher negatively predicted it. 
 The results indicate that coercive and normative institutional forces, as well as the 
institutional logics operating on organizations and the organizational networks they are 
embedded in, impact service provision and adoption of innovation. To promote adoption 
of pharmacotherapies into treatment, attention must be paid to the unique barriers and 
opportunities facing the adoption of each medication.  
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Organizational correlates of medication-assisted treatment (MAT)  
for opioid dependence in substance abuse treatment facilities:  
Examining how institutional forces shape treatment 
Maayan Lawental Schori  
Chapter 1 
Introduction 
 According to the latest national data available from 2010, 22.1 million persons 
ages 12 and older suffered from a substance use disorder (abuse or dependence) in the 
last year, corresponding to 8.7% of the U.S. population (Substance Abuse and Mental 
Health Services Administration [SAMHSA], 2011a). These people, in addition to those 
already receiving treatment in at a specialty facility, are classified by SAMSHA as 
needing treatment. Of the 23.1 persons classified as needing treatment, only 4.1 million 
received it; and for over half of those who did receive treatment, it was in the form of 
self-help groups. Therefore, the vast majority of people needing treatment do not receive 
any (SAMHSA, 2011a). This represents the lowest treatment penetration of any illness or 
condition (McGlynn et al., 2003). According to the latest data available, submitted to the 
Office of National Drug Control Policy (ONDCP) the economic costs associated with 
illicit drug use were estimated to be over $193 billion in 2007. Of this amount, only $3.7 
billion was spent on any form of treatment (National Drug Intelligence Center, 2011).  
 Several decades worth of research have demonstrated that medication-assisted 
treatment, particularly when combined with counseling, improves treatment outcomes for 
clients suffering from substance use disorders (Anton, Moak, Waid, Latham, Malcolm, & 
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Dian, 1999; Johnson, Eisenberg, Stitzer, Strain, Liebson, & Bigelow, 1995; Ling et al. 
1998; Monti et al. 2001; O’Malley, Jaffe, Chang, Schottenfeld, Meyer, & Rounsaville, 
1992; Volpicelli, Alterman, Hayashida, Volpicelli, J.R.; Alterman, A.I.; Hayashida, M. & 
O’Brien & O’Brien, 1992). Research has also shown that use of medication-assisted 
treatment results in reduced mortality and criminal activity rates (Greenfield & Fountain 
2000; Saxon & McCarty 2005; Woody et al. 2008). For instance, in a meta-analysis of 
three decades worth of research on methadone maintenance treatment (MMT), a 
pharmacotherapy used for treating persons struggling with opioid dependence, Marsch 
(1998) found that this form of treatment significantly reduced levels of illicit opiate use, 
HIV risk behavior, and criminal activity. The National Institute on Drug Abuse (NIDA, 
2009) and the World Health Organization (WHO, 2004) recommend methadone 
maintenance as the standard of treatment and care for opiate abuse. Though methadone is 
legal in all 50 U.S. States, issues remain surrounding proper dosage and length of 
maintenance. Buprenorphine/naloxone (aka Subutex® or Suboxone®), a newer 
pharmacotherapy for treatment of opioid dependence was approved for use in the U.S. in 
2002 and has been the focus of many recent clinical trials which have demonstrated its 
effectiveness (e.g. Amass et al., 2004; Fischer et al., 1999; Fudula et al., 2003; Johnson, 
Chutuape, Strain, Walsh, Stitzer, & Bigelow 2000; Ling et al., 2005; Ling, Wesson, 
Charuvastra, & Klett, 1996; Lintzeris, Bell, Bammer, Jolley, & Rushworth, 2002). While 
additional pharmacotherapies are being developed and tested and much attention has 
been focused in recent research on their effectiveness, this thesis will focus on the above-
mentioned opioid replacement therapies, methadone and buprenorphine/naloxone. 
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 Substance abuse treatment organizations have often been criticized for their slow 
adoption of new practices (Kimberly & McLellan, 2006; Knudsen & Roman, 2004; 
Lamb, Greenlick, & McCarthy, 1998; Sloboda & Schildhaus, 2002). While previous 
studies have looked at organizational processes in service provision (e.g. D’Aunno, 2006; 
D’Aunno, Sutton, & Price, 1991; Guerrero, 2009; Roman & Johnson, 2002; Simpson & 
Flynn, 2007), the influence of organizational factors on treatment has seldom been 
interpreted in the context of organizational theory. With the notable exception of 
D’Aunno and colleagues (D’Aunno, Sutton, & Price, 1991; D’Aunno, Vaughn, & 
McElroy, 1999), and very recent work by Roman and colleagues (Savage, Abraham, 
Knudsen, Tothrauff, & Roman, 2012) most scholars do not employ a comprehensive 
conceptual framework to identify organizational predictors, or to interpret results. As a 
result, research on organizational research in substance abuse treatment has tended to 
focus on top-down institutional forces shaping treatment. Scholars have largely 
underplayed the role of individual organizational actors, a focus of recent works in the 
field of institutional logics (Thornton & Ocasio, 2008). An atheoretical approach that is 
based on examining only those organizational factors which have been found to be 
significant predictors by previous research results in: (a) conscribing the universe of 
possible organizational predictors to those that have already been examined, thus 
ignoring the salience of new factors and unique processes predicted by theory, (b) failing 
to understand the complex and often contradictory processes that shape organizational 
behavior, and (c) undermining the theoretical framework underpinning the field of 
organizational substance abuse treatment research. 
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To improve the breadth of factors considered and the analytic methods used in 
explaining the provision of medication-assisted treatment, this thesis will apply the theory 
of institutional logics to examine an expanded set of organizational and institutional 
correlates of medication-assisted treatment in substance abuse treatment facilities, using a 
mixed methods approach. First, 30 qualitative interviews with decision makers in 
substance abuse treatment facilities will be used to develop an expanded set of 
organizational factors which could reasonably be expected to predict the provision of 
medication-assisted treatment. The interviews will also be used to frame the discussion of 
the results. Second, an additional analysis of The National Treatment Center Study 
(NTCS), a nationally representative dataset of substance abuse treatment facilities, will 
be conducted.  
The NTCS is the largest, most contemporary and comprehensive source available 
examining organizational variables. The survey to be analyzed in this thesis comes from 
405 private substance abuse treatment facilities in the U.S., conducted between 2002-
2004 by the Institute of Behavioral Research at the University of Georgia. This survey 
collected data pertaining to changes organizations, structure, staffing, and service 
delivery patterns in substance abuse treatment facilities. The data will be used to examine 
the extent to which factors identified by theory, previous literature and the qualitative 
interviews, contribute to explaining the organizational adoption of medication-assisted 
treatment. Furthermore, since buprenorphine/naloxone was approved for use in 2002 
(Amass et al., 2004; Brown, 2004; Ling et al., 2009; NIDA, 2006), this dataset provides a 
unique opportunity to look at early adoption of innovation in substance abuse treatment. 
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Rogers (2003) has pointed to the importance of studying early adoption of innovation in 
order to understand organizational characteristics that allow service providers to address 
client needs.  
The next chapter provides background on medication-assisted treatment and 
possible barriers to adoption of this form of treatment. The third chapter on the 
theoretical framework outlines neoinstitutional theory and the theory of institutional 
logics, the organizing conceptual framework used in this research. The fourth chapter 
reviews the literature describing organizational factors associated with the provision of 
services in substance abuse treatment. The review highlights the concepts of 
neoinstitutional theory and institutional logics, and will be used to generate general 
hypotheses about how organizational forces shape service provision. The fifth chapter 
provides an overview of the methods culminating in the hypotheses stated in terms of the 
operationalized variables. The sixth chapter details findings from both the qualitative and 
quantitative components of the study, respectively. Finally, an integrative discussion of 
the results and implications for future research will be presented in chapter seven. 
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Chapter 2 
Background 
The Organizational Field 
 Substance abuse treatment facilities in the U.S. 
Since 1992, the Substance Abuse and Mental Health Services Administration 
(SAMHSA) has been conducting an annual census of facilities providing treatment 
services in the U.S.1 In the National Survey of Substance Abuse Treatment Services (N-
SSATS) SAMHSA collects data on the location, organizational and client characteristics 
of treatment facilities and services throughout the 50 States, the District of Columbia, and 
other U.S. jurisdictions (e.g. Guam, Puerto Rico and US Territories).  
According to the latest report available, a little less than 1.2 million persons per 
year are treated in 13,339 substance abuse treatment facilities across the U.S. (see figure 
2.1. below). These include program level, clinic level and multi-site level facilities, but 
not jail or prison-based programs. All numbers in this section are based on a 91.4 percent 
survey response rate of the 2010 N-SSATS (SAMHSA, 2011b).  
The majority of facilities surveyed (58%) were private non-profit, a number that 
has remained relatively constant in recent years. Private for-profit facilities represented 
30 percent of all facilities in 2010, a five percent increase since 2003. Over 80 percent of 
all facilities offered outpatient care. These facilities served 90% of all clients. Non-
hospital based residential treatment was offered by nearly 26 percent of facilities, but 
received by only 9 percent of clients. Inpatient hospital treatment was offered by 6 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Similar data was previously collected by NIDA since the 1970s 
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percent of facilities, but accounted for only 1 percent of client care. Nine percent of all 
facilities offered opioid replacement therapy (i.e. methadone maintenance, 
buprenorphine/naloxone) between 2006-2010. However, these facilities served nearly a 
quarter of all clients. Sixty percent of facilities reported receiving Federal, State of local 
government funds, and 95 percent of all facilities reported that they were licensed, 
certified, or accredited by one or more agency or organization (SAMHSA, 2011b). 
Though the question was not asked in the latest survey, in a previous survey almost half 
of the facilities reported contracts with managed care organizations (SAMHSA, 2008). 
 
Figure 2.1. Location of treatment facilities in the U.S. on March 31st, 2008 
(SAMHSA, 2008) 
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Over 90 percent of all facilities provided screening for substance abuse for 
assessment and pre treatment services. Ninety percent provided comprehensive substance 
abuse assessment or diagnosis; nearly 67% of facilities screened for mental health 
disorders, and only 20% reported providing intermediate services when immediate 
admission was not possible. The prevailing clinical/therapeutic approaches, reported to be 
used always or often, were substance abuse counseling (95%) and relapse prevention 
(85%). Additional approaches reported to be used always, often or at least sometimes 
were cognitive-behavioral therapy (92%), motivational interviewing (87%), anger 
management (84%), brief intervention (82%), 12-step (80%), trauma-related counseling 
(67%), and contingency management/motivational incentives (58%) (SAMHSA, 2011b). 
Over eighty percent of facilities reported that they offered programs for needs of 
specific client types. Almost two fifths of the facilities offered services specifically 
tailored for clients with co-occurring mental health and substance abuse disorders. 
Roughly 30 percent of programs reported that they provided services for adult women, 
adolescents and DUI/DWI offenders each. Twenty-seven percent of facilities offered 
services for criminal justice clients and 25 percent offered specialty services for adult 
men. Among the less frequently offered were programs for pregnant or postpartum 
women (13%), persons with HIV or AIDS (9%), seniors or older adults (7%), and 
lesbian, gay, bisexual or transgender (LGBT) clients (6%) (SAMHSA, 2011b). 
 Finally, while some form of pharmacotherapy was offered by nearly 50% of 
facilities, most offered only medication for psychiatric disorders (34.6%). A little over 
11% offered methadone, while 18.4% offered buprenorphine/naloxone in 2010 
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(SAMHSA, 2011b). While the percentage of programs offering methadone has remained 
relatively steady since 2002 (the year in which buprenorphine/naloxone was approved for 
use), the percentage of programs adopting buprenorphine/naloxone has been steadily 
increasing. 
  
 Medication-assisted treatment for opioid dependence 
 Methadone and buprenorphine/naloxone are the two recommended 
pharmacotherapies for the treatment of opioid dependence (VA, 2009; Soyka, Kranzler, 
van den Brink, Krystal, Muller, & Kasper, 2011). They are considered the ‘gold standard’ 
for treatment, as numerous clinical trials have demonstrated their effectiveness (Oliva et 
al., 2011). Before describing these two forms of treatment and summarizing the evidence 
of their effectiveness, a brief overview of opiates and opioid dependence is provided. 
 Opiates and opioid dependence. 
 Opiates, including heroin, morphine and other prescription painkillers (such as 
OxyContin, Vicodin, and Fentanyl) are psychoactive substances that act on receptors in 
the brain, which also interact with endorphins. Endorphins are important in regulating 
pain and emotion. Thus, while prescribed use of certain painkillers can be highly 
beneficial, opiates can be highly addictive because of their euphorigenic properties 
(Brown, 2004; NIDA, 2006). This is particularly true for heroin, developed from opium 
(poppy) originally as a cough suppressant in 1985 (Brown, 2004).    
 Opioid dependence is a chronic relapsing condition characterized by compulsive 
self-administration of opioids that persists despite adverse consequences (Brown, 2004). 
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The ICD-10 defines dependence as “a cluster of physiological, behavioral, and cognitive 
phenomena in which the use of a substance or a class of substances takes on a much 
higher priority for a given individual than other behaviors that once had greater value.” 
(World Health Organization, 1992). According to the ICD-10, drug dependence 
manifests in compulsive substance use despite evidence of harm due to use, the presence 
of characteristic withdrawal phenomena upon discontinuation or drastic reduction of use, 
development of tolerance to the effects of the substance, and dysfunction in other life 
areas due to use and/or preoccupation with use (Brown, 2004).  
 Similarly, the DSM-IV (2004) defines dependence as ‘a maladaptive pattern of 
use, leading to clinically significant impairment or distress, as manifested by 3 or more 
diagnostic symptoms, occurring at any time in the same 12-month period. Symptoms can 
include: tolerance, as defined by either the need for markedly increased amounts of 
substance to achieve intoxication or desired effect or markedly diminished effect with 
continued use of the same amount of substance; withdrawal, as manifested by either the 
characteristic withdrawal syndrome for opiates (3 of: dysphoric mood, nausea or 
vomiting, muscle aches, lacrimation or rhinorrhea, diarrhea, yawning, fever, insomnia, 
gooseflesh, sweating) or the same (or a closely related) substance is taken to relieve or 
avoid withdrawal symptoms; substance taken in larger amounts over a longer time period 
than intended; persistent desire or repeated unsuccessful attempt to quit; much 
time/activity to obtain, use, recover; important social, occupational, or recreational 
activities are given up or reduced, and; continued use despite knowledge of adverse 
consequences (American Psychiatric Association, 1994). 
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 According to the National Survey on Drug Use and Health, an estimated 3.7 
million people had used heroin at some time in their lives (NSDUH, 2004), and 200,000 
of them reported using it within the month preceding the survey (SAMHSA, 2011a). An 
estimated 314,000 Americans used heroin in the past year, and the group that represented 
the highest number of those users were 26 or older. In 2003, over 55 percent of past year 
heroin users were classified with dependence on or abuse of heroin, and an estimated 
280,000 persons received treatment for heroin abuse (NSDUH, 2004). Heroin use, 
particularly when injected, raises major public health concerns. There are significant and 
costly medical illnesses heroin dependence, such as HIV, hepatitis C and other infectious 
diseases. The social and economic costs due to associated crime and poverty exceed those 
of most other drugs (Mark, Woody, Juday, & Kleber, 2001). In addition, 2 million 
persons reported initial use of nonmedical painkillers with almost the same number of 
persons classified as dependent on or abusing painkillers [NSDUH, 2011]. 
  
 Methadone. 
 Worldwide, methadone is the most widely studied and accepted form of 
medication therapy for opiate addicts (Mattick, Kimber, Breen, & Davoli, 2008; NIH 
Consensus Panel 1998; Farrell et al. 1994, Marsch, 1998). Developed in the 1940s to treat 
pain, methadone is an orally administered full mu-opioid (morphine-like) agonist that 
reduces the withdrawal symptoms of and represses cravings without bringing about the 
euphoric feeling associated with the use of illicit opioids (Centers for Disease Control 
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and Prevention, 2002; Donny, Walsh, Bigelow, Eissenberg, & Stitzer, 2002, Marsch, 
1998).  
 Methadone, administered daily, is regulated and offered only in licensed specialty 
treatment programs designed to offer treatment for opiate addicts. For decades, 
Methadone maintenance has been shown to reduce the frequency of opiate use 
(Langendam, van Brussel, Coutinho, & van Ameijden, 2001; Ling, 1976; Mattick et al., 
2008), mortality (Ward, Malrick, & Hall, 1994; Langendam et al., 2001),  and 
transmission of HIV (Ball, Lange, Myers, & Friedman, 1988; Des Jarlais et al., 1996). A 
recent meta-analysis of 11 clinical trials summarized the effectiveness of methadone 
maintenance for the treatment of heroin addiction compared to treatments that did not 
involve replacement therapy. The authors concluded that methadone was significantly 
more effective than non-medication treatments in retaining patients in treatment and in 
the suppression of heroin use as measured by self report and urine/hair analysis, but not 
statistically different in criminal activity or mortality (Mattick et al., 2008). 
  
 Buprenorphine/naloxone. 
 Buprenorphine/naloxone (marketed as Subutex® and Suboxone®) is a partial mu-
opioid agonist that acts on the same receptors as heroin and morphine, relieving drug 
cravings without producing the same intense "high" or dangerous side effects (NIDA, 
2006). Approved by the U.S. Food and Drug Administration in October 2002, 
buprenorphine/naloxone can be offered through community office-based settings (Amass 
et al., 2004; Brown, 2004; Ling et al., 2009; Mattick et al, 2008). Furthermore, 
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buprenorphine/naloxone treatment was implemented successfully in both inpatient and 
outpatient treatment settings (Amass et al, 2004). Consequently, buprenorphine/naloxone 
may present an appealing alternative for treatment providers and organizations that wish 
to expand their services but are unwilling or unable (for instance due to regulatory issues) 
to obtain a license for the use of methadone. To facilitate the dissemination of 
buprenorphine/naloxone, NIDA and SAMHSA's have recently developed and published 
training materials for interested providers (Ducharme, Knudsen, Roman, & Johnson, 
2007). 
 Numerous clinical trials have been conducted to examine the effectiveness of 
buprenorphine/naloxone (Ling &Wesson, 2003). In a recent meta-analysis of 24 clinical 
trials summarized the effectiveness of buprenorphine/naloxone for the treatment of heroin 
addiction compared to treatments that did not involve replacement therapy and compared 
to methadone maintenance. The authors found that buprenorphine/naloxone was 
significantly more effective than non-medication treatments in retaining patients in 
treatment and in the suppression of heroin use when provided in medium or high doses as 
measured by self-report and urine/hair analysis. They also found that 
buprenorphine/naloxone was less effective than methadone prescribed at adequate dose 
levels (Mattick et al., 2008). 
 Barriers to adoption. 
 Oliva and colleagues (2011) recognize that various pharmacotherapies, though 
considered to have a strong evidence-base, are largely underutilized in substance abuse 
treatment settings. Utilizing a multi-level framework, they describe in detail some of the 
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main system, provider and patient-level barriers to the adoption and use of 
pharmacoptherapies (Oliva, Maisel, Gordon, & Harris, 2011). 
 System-level barriers include Government and insurance policies that impact the 
availability and cost of services, program characteristics (e.g., treatment philosophy) and 
practices (e.g., suboptimal dosing), lack of pharmaceutical industry support compared 
with other psychiatric medications, and logistical issues such as lack of access to 
prescribing physicians, limited clinical and administrative support, cost concerns, issues 
with coordinating care, difficulties obtaining medications at local pharmacies, and the 
burden of laboratory testing. Provider-level barriers to the adoption of medication-
assisted treatment include informational barriers (e.g. inadequate training of lack of 
knowledge), provider perceptions and concerns regarding effectiveness and demand and 
their own ability to utilize these medications appropriately. In addition to cost and access, 
an important patient-level barrier is lack of information. Considerably less attention has 
been paid to research examining patient perspectives, knowledge, and attitudes regarding 
medication therapy, a possible avenue for future research (Oliva et al., 2011; see also 
McLellan, Lewis, O’Brien, & Kleber, 2000). 
 Though the authors do not utilize a theoretical framework to organize their review 
of the literature pertaining to barriers associated with the use of pharmacotherapies, their 
analysis supports the use of a multi-level approach when studying adoption and 
utilization of practices. The conceptual framework of neoinstitutional theory and 
institutional logics detailed in the next chapter can be used to examine how various 
organizational processes and practices are formed and shaped. This study proposes to 
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apply and test the framework to study the provision of pharmacotherapies in substance 
abuse treatment organizations in the U.S. Studies from the last couple of decades have 
been concerned with various forces that may explain or predict the provision of services 
in this organizational field. The following chapter also reviews the literature on how 
organizational practices are formed and shaped in the field of substance abuse treatment 
leading to research questions and hypotheses.  
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Chapter 3 
Conceptual Framework 
In an attempt to understand why organizations are so similar to one another, and 
why the adoption of new items and practices is often slow, neoinstitutional theorists 
argue that organizational practices are structured by processes originating in an 
organization’s institutional field (DiMaggio & Powell, 1983; Fligstein, 1990; Meyer & 
Rowan, 1977; Zucker, 1988). Organizational fields refer to a group of organizations that 
“constitute a recognized area of institutional life: key suppliers, resource and product 
consumers, regulatory agencies, and other organizations that produce similar services or 
products” (DiMaggio & Powell, 1983, p.148). Interactions among organizations within a 
particular field result in the emergence of clear interorganizational patterns, and the 
development of an understanding regarding the nature of their shared environment 
(DiMaggio & Powell, 1983). 
 
Neoinstitutional theory and forces influencing organization 
Neoinstitutional theory highlights the manner in which organizations become 
more like other organizations in their field as a result of external pressures exerted on 
them (DiMaggio & Powell, 1983; Fligstein, 1990; Meyer & Rowan, 1977; Zucker, 1988). 
This homogenization, or isomorphism as it is more widely referred to, is a ‘constraining 
process that forces one unit in a population to resemble other units that face the same set 
of environmental conditions’ (DiMaggio & Powell, 1983, p.149). Neoinstitutional theory 
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posits that individual actors are unable to visualize alternatives and thus they diffuse 
shared beliefs, or institutional myths, across organizations (Fligstein, 2001).  
DiMaggio and Powell (1983) describe three forms of institutional isomorphism: coercive, 
mimetic and normative.  
Coercive isomorphism, results from pressure exerted on organizations by other 
organizations on which they are dependent for funding or legitimacy. This pressure can 
be formal (e.g. government mandate, laws, regulatory agencies) or informal (i.e. societal 
and cultural expectations of the environment).  
Mimetic isomorphism results when organizations mimic other organizations that 
they view as successful in order to survive or gain legitimacy. By modeling others, 
organizations sometimes adopt innovations, without consideration of their effectiveness 
or efficiency. 
Normative isomorphism results from the pressures exerted by the norms that 
emerge in an organizational field through professionalization and standardization. 
Organizations find themselves steered to adopt prevalent norms, standards and practices 
in order to find legitimacy in their organizational field.  
Institutional isomorphism is hypothesized to progress even in the absence of any 
indication that the new models, practices or organizational structures being adopted are 
effective or efficient. Often is the case that the structure of an organization is a 
manifestation of the myths of the institutional environment, which pays little attention to 
what should be accomplished (Meyer & Rowan, 1973). In other words, in these cases 
efficiency is not the main priority (see also Thornton & Ocasio, 1999, 2008; Tolbert & 
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Zucker, 1983). DiMaggio and Powell (1983) suggested that if effectiveness is enhanced 
in a modeling organization (an organization that mimics others in its field), it is often a 
result of the organization being rewarded for its likeness to other organizations in its 
field, thereby gaining legitimacy, prestige and funding opportunities. Thus, an isomorphic 
organization is not necessarily more efficient than its less conforming peer.  
While neoinstitutional theory provides an important framework for examining 
organizational change and stability, it has often been critiqued for being overly 
deterministic, unidirectional (i.e. top-down) and for ignoring the role of agency 
(discussed below) in processes of organizational change (Cooney, 2007; Fligstein, 2001; 
Scott, 2008). Giddens (1984) argued that neoinstitutional theory treats individual actors 
as passive and powerless in the face of institutional forces exerted on them (see also 
Fligstein, 2001).  
Rational choice neoinstitutionalism emphasizes a fixed set of rules that allow for 
rational decision making processes among individual actors while sociological 
neoinstitutionalism emphasizes uncertainty and isomorphic processes that are led by 
professionals and governments. Neither form of neoinstitutionalism adequately considers 
the issue of agency - individuals’ power to act independently, to make choices, to 
mobilize resources in order to impact social structures in the face of prevalent 
institutional logics, rules and myths (Fligstein, 2001).  
A related issue, often neglected by neoinstitutionalists, is power. 
Neoinstitutionalism focuses on actors as disseminators of myths and rules, suggesting 
they have no real motive for taking action. Thus, neoinstitutionalism by itself cannot 
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answer questions pertaining to how and why new institutions emerge, which actors act, 
why they do so and what meanings exist or do not exist (Fligstein, 2001). Institutional 
logics, discussed in more detail the following section, extend neoinstitutional theory and 
provide a framework for better understanding conflicting institutional environments.  
Institutional logics 
 Institutional logics expands neoinstitutional theory’s focus on isomorphic 
institutional processes by incorporating the contradictory institutional forces at play in an 
organizational field. Institutional logics can be thought about as ‘taken-for-granted sets of 
understandings about what kinds of things exist, what kinds of practices might be 
deployed and what kinds of rationales could be offered to legitimate actions taken’ (Mohr 
& Guerra-Pearson, 2007). Further, institutional logics highlights the manner in which 
organizational practices are shaped by organizational actors, who in turn, are responding 
to their social locations in organization and within other networks (Thornton & Ocasio, 
2008). These multilevel environments both constrain behavior and enable agency 
(Friedland and Alford, 1991; Jackall, 1988; Thornton & Ocasio, 1999). In other words, 
the underlying logics of institutions both structures heterogeneity and homogeneity, as 
well as shape innovation and change in organizations (Thornton & Ocasio, 2008).  
 Institutional logics were first conceptualized by Alford and Friedland (1985) to 
explain inconsistent belief systems and practices in institutions (Friedland & Alford, 
1991). As mentioned above, institutional logics are similar to neoinstitutional theory in 
the emphasis on how organizational structure is shaped by institutional forces. However, 
the focus is not on isomorphism and conformity, but on how competing logics originating 
	  20	  	  
in diverse environments shape organizational behavior. Institutional logics shape rational 
behavior of individuals while these organizational actors change the institutional logics 
and shape the organizational structure (Thornton & Ocasio, 2008).   
 Individual values, beliefs and identities are embedded within the dominant 
institutional logics, while change and innovation are the result of interactions between 
agency and structure. Organizational form and adoption of innovations are thus explained 
by variation in prevailing institutional logics, rather than by isomorphic processes and 
conformity, thereby allowing for consideration of stability as well as heterogeneity, 
conflict, and change (Friedland & Alford, 1991; Jackell, 1988; Thornton & Ocasio, 1999, 
2008). Thus, the idea of institutional logics extends neoinstitutional theory by pointing 
out that organizational practices and structure are explained by different, often conflicting 
institutional environments, rather than by isomorphism and conformity. 
Three concepts enunciated by institutional logics theorists have special relevance 
to the field of innovative service provision in substance use treatment:  
 Competing organizational identities: Scholars have argued that organizational 
identities, and associated ideologies are constituted by sets of social codes, rules, rituals 
and interpretive schema that an organization is expected to possess (Hannan, Polos & 
Carroll, 2005; Polos, Hanan & Carroll, 2002) and utilize to define its purpose (meaning-
making). Organizational actors become the carriers of organizational identities (Hsu & 
Hanan, 2005). It is often the case that different sets of organizational actors adhere to 
different identities. Hsu and Hanan (2005) note that within organizations, ideological 
differences may exist between top managers and entry-level workers, permanent and 
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temporary employees, and female and male workers, whereas in the institutional field, 
differences may exist between extra-organizational actors such as regulators, critics, 
industry analysts, consumers and clients, and potential employees.  
 Differences in organizational identities can trigger change and innovation. 
Examining changes in the U.S. brewing industry, Carroll and Swaminathan (2000) note 
that consolidation between local brewing firms with mass-produced industrial brewing 
practices produced two unique forms of brewing that were in opposition to national 
breweries: microbrewery and brewpubs that prioritized small-scale handcrafted methods 
of beer production. Similarly, food-cooperatives have incorporated innovative and 
competing identities (McEvily & Ingram, 2003). Food co-ops that had adopted the 
practices of large supermarkets by creating hierarchical organizational structures, went 
back to cooperative structures, when for-profit chains began entering the natural food 
market niche. Clashes in identities between the two types of organizations forced smaller 
food-co-ops to distinguish themselves by adopting innovative horizontal and democratic 
organizational bureaucracies. This process of adoption of new ways due to identity 
competition is enunciated in a study on French gastronomy where Rao, Monin and 
Durand (2003) document the way in which the nouvelle cuisine movement led elite chefs 
schooled in classical cuisine to adopt new approaches, identities and technologies. In this 
case, adoption was a result of collective identity processes whereby organizational actors 
plugged into the interpretive schema (or movement frame) of the nouvelle cuisine 
movement in order to change old institutional identities. 
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 The salience of milieus: Drawing on Bourdieu’s (1988) notion of habitus to 
describe the extra-organizational institutional field which structures organizational 
behaviors, Everett (2002) notes that organizational actors belong to networks and milieus 
which are marked by particular cultural practices and beliefs. The cultural ethos attached 
to these milieus shapes actors’ orientations and have the potential to influence their 
organizational behaviors and choices. Ozbilgin & Tatli (2005) emphasize the importance 
of Bourdieu’s formulation of social and cultural capital in understanding the way 
organizational actors draw on various repertoires of capital in making decisions about 
organizational practices. They note that social relationships outside the organization (that 
help to build social capital), as well as the kinds of symbolic, ideological and affective 
processes that are nurtured (thus developing cultural capital) in these external milieus, are 
important influencers of behavior in organizations. In explaining the manner in which 
nouvelle cuisine redefined French culinary traditions in France in the 1970s, Rao & 
colleagues (2003) for instance, emphasize the manner in which acclaimed French chefs 
were influenced by the cultural networks they were embedded in at the time, many of 
which were instrumental in critiquing the status quo in other fields like the government, 
theatre, the arts and the humanities. Similarly, examining the way welfare workers 
negotiated rigid welfare-to-work organizational rules at welfare agencies, Cooney (2007) 
found that their personal connections to families and friends who were finding it hard to 
deal with the lack of jobs at the time, made them resist an organizational ethos that 
blamed welfare recipients for being unemployed.  
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 Embedded agency: Institutional logic scholars note that organizational actors and 
organizations, embedded as they are in organizations and extra-organizational 
institutional fields, are shaped by organizational and institutional processes, but 
simultaneously have the ability to shape these processes themselves (Battilana, 2006; 
Friedland & Alford, 1991; Seo & Creed, 2002; Thornton & Ocasio, 2008). Organizations 
and institutions thus both constrain agency, but are also subject to it (Giddens, 1984; 
Sewell, 1992). Legitimacy, valence, power and leadership characterize the modes through 
which embedded actors achieve change and re-shape the structural processes that seek to 
shape them (Thornton & Ocasio, 2008).  
Summary 
Institutional logics as a theory considers the processes of the interplay between 
multiple ideal types present in the organizational field, and of the strategizing that occurs 
on the part of agency. While many neo-institutional theorists also discuss the multiple 
levels of institutions present, institutional logic theorists combine this discussion with a 
discussion of the role of agency embedded within organizations.  
Thornton and Ocasio (2008), in discussing common misconceptions regarding 
institutional logics, point out that ‘ideal types are not a description of what happens in an 
organizational field. Ideal types are formal analytical models by which to compare 
empirical observations across institutions’ (p.119). They also point out that many studies 
consider ideal types and develop typologies of those ideal types within an organizational 
field, but fail to tie their analysis back to the institutional orders of the inter-institutional 
system.  
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Thus, in addition to considering the various logics that are at play in an 
organizational field, we must focus on the process of strategizing on the part of agency. 
As stated by Thornton and Ocasio (2008), ‘institutional logics, do not emerge from 
institutional fields – they are logically instantiated and enacted in organizational fields 
and in other places such as markets, industries and organizations’ (p.119). While 
considering ideal types of institutional forces in a particular field is important, the 
contribution of institutional logics is the process of local enactment of picking a 
particular logic over another, mixing logics, and bringing in personal logics from various 
networks. 
 In conclusion, the theory of institutional logics suggests that in order to 
paint a more detailed picture of how organizational practices are formed and shaped in a 
particular organizational field multiple factors and the interaction between them ought to 
be considered. Specifically, consideration should be given to the role of agency and the 
various networks they are embedded in, ideal types of institutionalisms present in the 
field and the (sometimes conflicting) logics related to them, and structural factors such as 
market forces, or internal and external organizational characteristics. 
 This study aims to explore the role these factors play in the adoption of 
medication-assisted treatment within the organizational field of substance abuse 
treatment. To this end, the following section provides an integrated review of previous 
organizational and institutional literature in the field.  
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Chapter 4 
Literature Review 
Though the conceptual model of institutional logics detailed in the previous 
chapter can be used to examine how various organizational processes and practices are 
formed and shaped, this study proposes to apply and test the framework to study the 
adoption of medication-assisted treatment in substance abuse treatment organizations in 
the U.S. Studies from the last couple of decades have been concerned with various forces 
that may explain or predict the adoption of new practices in this organizational field. The 
following section reviews the literature on how organizational practices are formed and 
shaped in the field of substance abuse treatment leading to research questions and 
hypotheses.  
 
Neoinstitutionalism, Institutional Logics and Substance Abuse Treatment 
Researchers have pointed to a substantial gap between the practices that research 
has shown to be effective and the practices that are utilized in the field of substance abuse 
treatment. In an effort to understand this gap, scholars have focused their attention on the 
role of institutional and organizational-level factors in the provision and utilization of 
services and in shaping organizational practices. They have pointed to the importance of 
studying substance abuse treatment at these levels as a means to inform decision makers 
and improve the quality of care (i.e. D’Aunno, 2006; Durkin, 2002; Hasenfeld, 2008). 
Substance abuse treatment organizations have often been criticized for their slow 
adoption of new practices (Knudsen & Roman, 2004; Lamb et al., 1998; Roman & 
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Johnson, 2002; Sloboda & Schildhaus, 2002), with some scholars suggesting that various 
organizational characteristics play a significant role in explaining the adoption and 
implementation of new practices and technologies (e.g. D’Aunno, 2006; D’Aunno et al., 
1991; Guerrero, 2009; Roman & Johnson, 2002; Simpson & Flynn, 2007). Of particular 
importance to adoption of innovations in substance abuse treatment are organizations’ 
institutional environments, such as funding sources, licensing and accreditation agencies, 
and ownership, that may demand (or hinder) the adoption of new practices (Baum & 
Oliver, 1992; D’Aunno, 2006; Ghose, 2006, 2008; Hasenfeld, 1992).  
While Simpson and Flynn focused mostly on organizational factors that are 
considered to be internal to the organization (such as motivation, institutional resources 
and staff attributes), D’Aunno (2006) emphasized the role of external institutional 
demands such as ownership, size of the organization, accreditation and managed care 
arrangements. Institutional theory scholars have described an interlocking system of 
institutional forces that shape organizational practices. The conceptual framework 
described by neoinstitutional theory and institutional logics is useful in understanding the 
organizational practices of substance abuse treatment facilities  
 
Institutional Forces: Coercive and Normative 
 Both coercive, as well as normative forces influence service provision in 
substance abuse treatment programs. Coercive forces are associated with the control 
exerted by funding, licensing and parental organizational sources. Normative forces in 
substance abuse treatment are characterized by managerial attitudes that shape the norms 
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associated with service provision, as well as client characteristics that shape the standards 
of care associated with certain types of client profiles. 
Coercive institutional forces 
Funding and managed care arrangements: Treatment services rely mostly on 
public funding and insurance payments (Durkin, 2002; SAMHSA, 2011b), which come 
with ties (D’Aunno, 2006). Licensing and professional accreditation agencies can also 
influence services provided (D’Aunno, 2006), as can managed care firms (Durkin, 2002; 
Lemak & Alexander, 2001; Sosin, 2002). The growth of managed care as a source of 
funding in substance abuse treatment has been extensive in recent years (Alexander, 
Lemak & Campbell, 2003). Scholars have found that managed care regulation is 
negatively correlated with treatment intensity (Lemak & Alexander, 2001) and the 
number of services provided (Corcoran & Vandiver, 1996; Gold, Hurley, Lake, Ensor & 
Berenson, 1995; Olmstead, White & Sindelar, 2004), limits autonomy of the provider 
(Alexander & Lemak, 1997; Mechanic, Schlesinger, & McAlpine, 1995; Schlesinger, 
Dorward, & Epstein, 1996; Schwartz & Wetzler, 1998), does not increase technical 
efficiency in service provision (Alexander, Wheeler, Nahra & Lemak, 1998) and 
increases relapse rates (Sosin, 2005). In their study of early adoption of 
buprenorphine/naloxone, Knudsen and colleagues (Knudsen, Ducharme & Roman, 2006) 
found that private centers were significantly more likely than public centers to report 
current use of buprenorphine/naloxone.  
Licensing: Ninety-five percent of substance abuse treatment programs in the U.S. 
reported being licensed, certified or accredited by at least one agency (81% by the their 
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state), 47% reported having agreements or contract with managed care firms, and 60% 
receive either federal, state or local government funding (SAMHSA, 2008). These high 
percentages suggest that demands made by these agencies are influential in determining 
services offered in substance abuse treatment programs. Research has shown this to be 
the case with mental health services in substance abuse treatment (Durkin, 2002), and in 
HIV prevention (D’Aunno et al., 1999). Facilities accredited by the Joint Commission on 
the Accreditation of Healthcare Organizations (JCAHO) were more likely to provide 
primary care and mental health services (Friedmann, Alexander & D’Aunno, 1999; 
D’Aunno, 2006), physical exams and routine medical care (Durkin, 2002), use 
antidepressants (Knudsen, Ducharme, & Roman, 2007b) and be early adopters of 
buprenorphine/naloxone (Knudsen et al, 2006). National and state licensing agencies are 
likely to have a broader picture of addiction, HIV and the importance of reducing HIV 
rates among intravenous drug users (D’Aunno et al., 1999).  
Parental organizational control: Scholars have argued that external agencies 
influence organizations’ adoption of practices and policies, specifically agencies on 
which the organization relies on for resources (Pfeffer & Salancik, 1978) and legitimacy 
(D’Aunno, 2006; DiMaggio & Powell, 1983). Parent organizations, such as hospitals or 
mental health centers are an important aspect of an organization’s external environment. 
Research has shown that the type of parent organizations is an explanatory factor in the 
provision of services (D’Aunno et al., 1991, 1999; Ghose, 2006) and outcome of 
treatment (Ghose, 2008). D’Aunno and colleagues (1999) note that parent facilities tend 
to provide more financial and resource support to substance abuse facilities that adopt 
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methods, technologies and ideologies that are similar to their own. For instance, units 
affiliated with hospitals were more likely to provide medical care, HIV testing and HIV 
counseling services (D’Aunno, 2006; D’Aunno et al., 1999). Knudsen and colleagues 
(2006) found that early adoption of buprenorphine/naloxone was also positively 
associated with being located in a hospital setting.  
The research suggests that coercive forces are at play in substance abuse treatment 
facilities:  
1a) I propose that centers that have state licensing, JCAHO or CARF 
accreditation and a parent organization that is a medical facility will be 
more likely to provide medication-assisted treatment and be early 
adopters of new medication-assisted treatment modalities than 
organizations who do not have state licensing, JCAHO or CARF 
accreditation or parent organization that is a medical facility.  
1b) Further, I propose that centers with a higher proportion of funding 
derived from managed care and those who report greater impact by 
managed care arrangements will be less likely to provide medication-
assisted treatment and less likely to be early adopters of new medication-
assisted treatment modalities than organizations with lower proportions of 
funding derived from managed care and those who report less impact of 
managed care arrangements. 
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Normative institutional forces 
Norms in a substance abuse treatment agency are established through managerial 
attitudes and orientations as well as the kinds of clients an agency caters to. 
Managerial attitudes: Managerial support for new practices is often crucial in 
the adoption process (D’Aunno et al., 1991; Klein & Sorra, 1996). For instance, D’Aunno 
and colleagues (1999) studied the adoption of HIV prevention practices in outpatient 
substance abuse treatment units and found that adoption was more likely when managers 
supported the efforts. 
 D’Aunno and colleagues stress the key role that institutional beliefs and norms 
play in the adoption of new practices in substance abuse treatment organizations 
(D’Aunno, 2006; D’Aunno et al., 1991; D’Aunno et al., 1999). Thus, adoption of 
organizational practices is often shaped by values within the larger institutional 
environment, rather than on efficiency (D’Aunno, 2006; Scott, 2008).  
Rosenberg and Phillips (2003) studied attitudes towards harm reduction among 
providers of substance abuse treatment in the U.S. They found that while 50% of 
respondents (mostly persons in clinical and managerial positions) rated several forms of 
harm reduction as somewhat or completely acceptable; the interventions themselves were 
not widely available at their agencies. For instance, only 1% of agencies offered needle 
exchange programs, 9% offered long-term methadone maintenance, and 23% and 38% 
accepted non-abstinence as final and intermediate treatment goals, respectively. For most 
forms of harm reduction included in the study, the main reason reported for lack of 
availability was inconsistency with the agency’s philosophy, followed by lack of 
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resources and funding. For non-abstinence treatment goals, the main reasons provided by 
respondents were inconsistency with the agency’s philosophy, not wanting to send the 
wrong message to clients, and belief that these goals are ineffective. Though the authors 
collected some organizational level data, their study remained descriptive in nature, and 
possible associations between the availability of harm reduction strategies and 
characteristics of the agencies and staff were not explored. 
Client Characteristics: Norms in the types of services offered are also 
established by the types of clients being served by agencies. Hasenfeld (1992) notes that 
clients comprise the “raw material” for human service agencies and often dictate the 
types of treatment and service technologies adopted by the organization. Examining the 
extent to which psychologists accept harm reduction practices based on characteristics of 
their clients, Wryobeck and Rosenberg (2005) found that previous treatment attempts and 
HIV status were positively associated with the acceptability of needle exchange among 
psychologists, while other client characteristics, such as gender, race, employment status 
and criminal history were not. The acceptability of short-term methadone was 
significantly associated with client populations having a longer history of use, and with 
more previous treatment episodes. In a sample of over 2,300 specialized substance abuse 
treatment facilities in the U.S., Ghose (2006) found that higher proportions of clients 
vulnerable to HIV infection were positively associated with the provision of specialized 
substance abuse treatment to seropositive clients. Another study, found that higher 
percentages of relapsers increased the likelihood a center will use naltrexone (Roman & 
Johnson, 2002). Early adoption of buprenorphine/naloxone was found to be associated 
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with the percentage of opiate-dependent clients (Knudsen et al., 2006). These findings 
suggest that substance abuse treatment facilities’ orientation might be shaped by client 
characteristics.  
Taken together, these findings suggest that managerial attitudes and client 
characteristics shape the normative environment with respect to treatment modality in a 
substance abuse facility.  
2a) Thus, I propose that centers whose managers are more positive 
towards medication-assisted treatment will be more likely to provide them 
and be early-adopters of new medication-assisted treatment modalities 
than centers whose managers are less positive.  
2b) I also propose that centers with higher proportions of clients with 
more serious drug and drug-related problems (e.g. opiate users, relapsers, 
dual-diagnosis) will be more likely to provide medication-assisted 
treatment and be early adopters of new medication-assisted treatment 
modalities than centers with lower proportions or these clients.  
 
Institutional Logics 
Several organizational factors that influence substance abuse treatment highlight 
the manner in which institutional logics shape service provision. Specifically, service 
provision is influenced by competing logics associated with different types of treatment 
ideologies, the types of milieu that providers are embedded in, embedded agency as 
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characterized by organizational age and size, as well as by characteristics of its leadership 
and their support for provision of services. 
Competing Identity logics 
D’Aunno and colleagues (1991) explored the recent changes in the substance 
abuse treatment system treatment by focusing on the merging of substance abuse and 
mental health treatment sectors, each of which was dominated by a different identity, and 
associated treatment ideology. The mental health orientation was embedded in a 
psychological perspective with degreed professionals providing treatment, while the 12-
step orientation, based in an abstinence-only approach was implemented through 
recovering (often non-degreed) counselors providing the majority of treatment. Each 
ideology brought with it a set of underlying assumptions regarding the etiology of 
addiction, as well as a different set of technologies. Treatment units operating in this 
environment were thus subject to two beliefs systems, or sets of ideological logics, which 
were often at odds. The mental health approach favored therapy and evidence-based 
practices, while the abstinence approach relied on modeling and mentoring by those in 
recovery, and attendance of 12-step recovery groups. Similarly, Ghose (2006) found that 
a treatment program’s modality was a manifestation of its ideology and internal ethos: 
methadone-maintenance programs that were partial to harm reduction methods were 
more likely to offer specialized treatment services to seropositive clients.  
D’Aunno and collogues (1991) studied ‘hybrid units’, treatment units that provide 
substance abuse services alongside mental health services. While acknowledging that 
each individual sector was dominated by a fairly distinct set of logics, they proposed that 
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hybrid units borrow from both sets, which were often at odds. Hybrid units, or mental 
health services that added a drug abuse component to their service, were exposed to new 
practices and beliefs. This exposure led to pressures of gaining legitimacy in the drug 
abuse sector on the one hand, but also being forced to adopt new, evidence-based 
treatment practices in order to stay legitimate in the mental health field. The authors 
proposed that hybrid units would incorporate practices consistent with both sets of 
beliefs, practices that might be ‘structurally incompatible’ with each other. Furthermore, 
they proposed that since organizations could not incorporate every new conflicting 
practice, they would favor those that helped them achieve a minimum level of legitimacy 
in the conflicting institutional environments. Consequently, they found that hybrid units 
emphasized the hiring of professionals more than drug abuse treatment units and the 
hiring of personnel in recovery more than mental health units. They argue that the 
inconsistent practices exhibited by hybrid units were a byproduct of the addition of 
abstinence as a treatment goal; that these units were not abandoning traditional mental 
health practices, but rather, mixing them with new practices, a phenomenon they termed 
‘partial adaptation’. 
The literature in this section suggests that competing identity logics influence the 
provision of services. Following D’Aunno’s lead, I propose that institutional identities 
(and associated ideological logics) as measured by the proportion of counselors in 
recovery and degreed counselors, and by centers’ emphasis on 12-step and medical 
models shape a facility’s decision to provide services.  
3a) I propose that centers with higher proportions of recovering 
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counselors on staff with be less likely to offer medication-assisted 
treatment and less likely to be early adopters of new medication-assisted 
treatment modalities than centers with lower proportions of recovering 
counselors on staff.  
3b) Further, I propose that centers with higher proportions of degreed 
staff will be more likely to offer medication-assisted treatment and be 
early adopters of new medication-assisted treatment modalities than 
centers with lower proportions of degreed staff.  
3c) I also propose that centers with stronger emphasis on 12-step 
approaches will be less likely to offer medication-assisted treatment and 
less likely to be early adopters of new medication-assisted treatment 
modalities than centers with lower emphasis on 12-step approaches, and, 
3d) that centers with a higher emphasis on the medical model will be more 
likely to offer medication-assisted treatment and be early adopters of new 
medication-assisted treatment modalities than centers with lower 
emphasis on the medical model. 
 
The salience of provider milieus 
While institutional logics emphasize the salience of habitus and external 
networks, scholars of substance abuse treatment facilities for the most part, have not 
explored the way the external habitus influences organizational processes. There is 
however, some evidence to suggest that it may play a crucial role in influencing 
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organizational decisions. D’Aunno and colleagues (1999) for instance, found that the 
more time managers spent in research conferences or professional meetings, the more 
likely they were to be familiar with new practices (like incorporating outreach services 
for clients) and support their adoption. Similarly, summarizing extra-organizational 
factors that influence service provision, D’Aunno (2006) notes that units whose directors 
were linked to external professional networks were more likely to provide HIV 
prevention, have collaborative relationships with other agencies and survive over time. 
Knudsen and colleagues (Knudsen, Abraham, Johnson, & Roman, 2009) linked the 
adoption of buprenorphine/naloxone to involvement in a buprenorphine/naloxone 
protocol. 
I propose that milieus that support evidence-based practices will encourage 
managers to incorporate medication-assisted treatment. However, organizational actors 
are also connected to another important milieu consisting of persons in recovery and 
treatment alumni who have completed the program. This is especially true for those 
providers who are recovering themselves and are connected to those in recovery. Given 
the abstinence-based ideologies that people in recovery tend to adhere to (D’Aunno et al., 
1999) I propose that these milieus would nurture a resistance to medication-assisted 
treatment.  
4a) Therefore, I propose that centers with stronger connections to 
substance abuse treatment research networks will be more likely to offer 
medication-assisted treatment and be early adopters of new medication-
assisted treatment modalities..  
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4b) I also propose that centers with stronger connections to 12-step 
recovery alumni networks will be less likely to offer medication-assisted 
treatment and less likely to be early adopters of new medication-assisted 
treatment modalities.. 
 
Embedded agency 
Institutional logic scholars (Thornton & Ocasio, 2008) call attention to agency on 
the part of organizations and organizational actors, that is sparked by being embedded in 
institutional fields and organizational structures. While being entrenched in these 
structures can result in normative organizational behavior, it can also lead to the ability to 
make changes because of the power that is associated with familiarity with the field, and 
credibility within it. The length of tenure of both facility and managers, as well as the size 
of a facility measure the level of embeddedness and credibility within the treatment field.  
Ghose (2006) found that size of agency (the number of clients served) was 
positively associated with the provision of specialized substance abuse treatment to 
seropositive clients. Another study found that size was positively associated with the 
early adoption of buprenorphine/naloxone (Knudsen et al., 2006). In their study on 
adoption and implementation of a new treatment technology, naltrexone (a drug that 
reduces the rewarding aspects of drug use) in privately funded substance abuse treatment 
centers in the U.S., Roman and Johnson (2002) found that adoption was positively 
associated with the age of the treatment program. Older centers were more likely to adopt 
naltrexone. Moreover, the tenure of managers in the field was also positively associated 
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with offering naltrexone. D’Aunno et al. (1999) also found that larger mental health-
substance use hybrid facilities were more likely than smaller facilities of the same kind to 
depart from an exclusively abstinence-based model. They concluded that prevailing 
mental health practices were more institutionalized in larger organizations, thus allowing 
them to resist the abstinence-only treatment modality that accompanied mergers with 
substance abuse treatment facilities. 
 The literature in this section suggests that embeddedness of actors in an 
organization or an organization in an organizational field can at times allow actors and 
organizations to innovate, buck prevailing trends and instigate change.  
5a) Therefore, I propose that centers whose managers are more embedded 
in an organization (as indicated by the length of their tenure) will be more 
likely to offer medication-assisted treatment and be early adopters of new 
medication-assisted treatment modalities than centers whose managers 
are less embedded in an organization.  
5b) I also propose that centers that are more embedded within their 
organizational field (as indicated by their size and age) will be more likely 
to offer medication-assisted treatment and be early adopters of new 
medication-assisted treatment modalities..  
5c) Finally, I propose embeddedness will interact with the correlates 
described in the previous sections to influence the provision of 
medication-assisted treatment to a greater degree.  
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Summary of proposals emerging from the literature review 
 The literature review indicates that the provision of medication-assisted treatment 
services being provided at a treatment facility is shaped by neoinstitutional forces, which 
are coercive and normative, as well as by institutional logics processes like competing 
ideologies, the salience of provider milieus and embedded agency.  
Neoinstitutional forces 
Hypothesis 1a (coercive): I propose that centers that have state licensing, JCAHO 
or CARF accreditation and a parent organization that is a medical facility will be more 
likely to provide medication-assisted treatment and be early adopters of new medication-
assisted treatment modalities than organizations who do not have state licensing, JCAHO 
or CARF accreditation or parent organization that is a medical facility.  
Hypothesis 1b (coercive): I propose that centers with a higher proportion of 
funding derived from managed care and those who report greater impact by managed 
care arrangements will be less likely to provide medication-assisted treatment and less 
likely to be early adopters of new medication-assisted treatment modalities than 
organizations with lower proportions of funding derived from managed care and those 
who report less impact of managed care arrangements. 
Hypothesis 2a (normative): I propose that centers whose managers are more 
positive towards medication-assisted treatment will be more likely to provide them and be 
early-adopters of new medication-assisted treatment modalities than centers whose 
managers are less positive.  
Hypothesis 2b (normative): I propose that centers with higher proportions of 
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clients with more serious drug and drug-related problems (e.g. opiate users, relapsers, 
dual-diagnosis) will be more likely to provide medication-assisted treatment and be early 
adopters of new medication-assisted treatment modalities than centers with lower 
proportions or these clients. 
Institutional logics processes 
Hypothesis 3a (competing identity logics): I propose that centers with higher 
proportions of recovering counselors on staff with be less likely to offer medication-
assisted treatment and less likely to be early adopters of new medication-assisted 
treatment modalities than centers with lower proportions of recovering counselors on 
staff.  
Hypothesis 3b (competing identity logics): I propose that centers with higher 
proportions of degreed staff will be more likely to offer medication-assisted treatment 
and be early adopters of new medication-assisted treatment modalities than centers with 
lower proportions of degreed staff.  
Hypothesis 3c (competing identity logics): I propose that centers with stronger 
emphasis on 12-step approaches will be less likely to offer medication-assisted treatment 
and be early adopters of new medication-assisted treatment modalities than centers with 
lower emphasis on 12-step approaches. 
Hypothesis 3d (competing identity logics): I propose that centers with a higher 
emphasis on the medical model will be more likely to offer medication-assisted treatment 
and be early adopters of new medication-assisted treatment modalities than centers with 
lower emphasis on the medical model. 
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Hypothesis 4a (salience of milieus): I propose that centers with stronger 
connections to substance abuse treatment research networks will be more likely to offer 
medication-assisted treatment and be early adopters of new medication-assisted 
treatment modalities.. 
Hypothesis 4b (salience of milieus): I propose that centers with stronger 
connections to 12-step recovery alumni networks will be less likely to offer medication-
assisted treatment and less likely to be early adopters of new medication-assisted 
treatment modalities. 
Hypothesis 5a (embedded agency): I propose that centers whose managers are 
more embedded in an organization (as indicated by the length of their tenure) will be 
more likely to offer medication-assisted treatment and be early adopters of new 
medication-assisted treatment modalities than centers whose managers are less 
embedded in an organization. 
 Hypothesis 5b (embedded agency): I propose that centers that are more 
embedded within their organizational field (as indicated by their size and age) will be 
more likely to offer medication-assisted treatment and be early adopters of new 
medication-assisted treatment modalities.  
 Hypothesis 5c (embedded agency): I propose embeddedness will interact with the 
correlates described in the previous sections to influence the provision of medication-
assisted treatment to a greater degree.  
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Gaps and Limitations of Current Research 
The studies described above are useful in identifying many predictors crucial to 
the adoption of new practices, yet several gaps can be identified. Many of the studies, 
with the notable exception of D’Aunno and colleagues do not attempt to organize their 
hypotheses based on a theoretical framework. Furthermore, most studies reviewed 
explore only organizational and/or institutional level factors, and tend to underplay the 
possible role of agency in the adoption of practices. For instance, D’Aunno and 
colleagues (1991) discuss how strong evidence or emotional and ideological arguments in 
favor a particular practice may tempt managers (individuals) and organizations to 
abandon one practice for another, hinting that agency might has a role in organizational 
processes. However, they do not examine the unique role of agency or the strategizing 
that occurs. This study addresses this issue by using the more comprehensive framework 
of institutional logics to explore technological adoption. 
Qualitative studies exploring possible individual-level factors pertinent to the 
adoption of new practices in substance abuse treatment are rare. As a result, discussion of 
the unique as well as combined effects of these various levels of analysis is scarce, and 
discussion of the processes that shape organizational practices is missing. This study will 
employs qualitative methods to examine the various institutional forces in the field of 
substance abuse treatment, and to explore the logics at play and the role of agency in 
bringing change to dominant logics.  
The proposed study addresses these limitations by using a multi-level conceptual 
framework to identify possible predictors to the adoption of new practices, and to 
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interpret the findings. In particular, this study attempts to introduce the role of agency 
into decision-making regarding the adoption of practices in substance abuse treatment, in 
addition to exploring organizational characteristics and institutional demands. Further, 
this study uses qualitative methods to enrich the knowledge of the various forces, such as 
the role of agency and networks, contributing to or hindering the adoption of new 
practices. 
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Chapter 5 
Research Design and Methods 
Overview 
This study proposes to explore the hypotheses presented in the previous chapter 
using a mixed-methods approach. Qualitative interviews with managerial level staff at 
substance abuse treatment centers in the greater Philadelphia area and New York City 
were conducted. The interviews were semi-structured and explored perceptions of 
treatment philosophy, the merging of substance abuse and mental health, managed care in 
substance abuse treatment, services, funding, licensing and accreditation and personal 
and professional networks. The content of these interviews was transcribed from audio 
recordings and analyzed to reveal recurring themes and answer the research questions. 
Secondary statistical analysis of a national data set of private substance abuse treatment 
centers and their characteristics was then used to test the research hypotheses 
quantitatively. 
 
Qualitative analysis plan  
In order to explore institutional forces and institutional logics, and the manner in 
which they influence the provision of medication-assisted treatment, I conducted 30 
semi-structured qualitative interviews with managers of substance use treatment facilities 
operating in the greater Philadelphia area and in New York City. The first wave of 
facilities was selected from a list of treatment facilities available at the Treatment 
Research Institute (TRI) in Philadelphia, with which the investigators are affiliated. The 
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TRI host the Delaware Valley (DV) node of NIDA’s Clinical Trials Network (CTN) and 
therefore has contact with various treatment organizations in the area. Initial contact with 
the mangers of these facilities was facilitated by the fact that many of them have worked 
with TRI in the past. These facilities were in the Greater Philadelphia area. The second 
wave was sampled through snowball sampling methods whereby managers in the first 
wave referred me to other managers to the study or put me in touch with them, several of 
these referrals were to facilities in New York City (a place frequented by the investigator 
for another project).  
Managers were contacted by phone and/or e-mail and the purpose of the study 
and the reason for their selection was explained. A face-to-face interview was arranged if 
they agreed to participate in the study (no one who was approached declined 
participation). Interviews typically lasted about an hour. All interviews were taped and 
transcribed. Interviews explored the types of services provided and the processes shaping 
decisions to provide them and information about personnel, clientele, funding, treatment 
philosophy, services and professional networks (see appendix 1).  
Inclusion and exclusion criteria: Subjects had to be (1) one of the principal 
decision-making managers of his or her substance abuse treatment facility, (2) able to 
communicate in English, and (3) understand and sign the consent form.  
Data collection and analysis: All interviews were transcribed by the author for 
textual analysis. A grounded theory approach was utilized by the author to code the 
interviews (Glaser & Strauss, 1967). Concepts that emerged from earlier data informed 
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the coding of subsequent interviews. The first round of coding identified primary codes. 
Subsequent rounds identified axial codes.   
 Concepts related to the content areas described in the literature review – coercive 
and normative forces, competing identities, milieus and embedded agency were explored. 
They were be used to further operationalize the quantitative variables described below 
when appropriate, and to frame and enrich the discussion of the results. 
Secondary analysis plan:  
Sampling: The National Treatment Center Study (NTCS) is a family of projects 
dating back to 1995, designed to document and track changes in the organization, 
structure, staffing, and service delivery patterns of substance abuse treatment programs 
throughout the U.S. For the proposed study, I used the NTCS, which is a nationally 
representative survey of 405 private substance abuse treatment facilities, conducted 
between 2002-2004 by a group of researchers at the Institute of Behavioral Research at 
the University of Georgia. This is the fourth time this survey of privately funded centers 
has been conducted (Roman & Johnson, 2004). This dataset is not available for public 
use and was graciously made available to the researcher by the principal investigator, Dr. 
Paul Roman, and his colleagues at the University of Georgia.  
 Centers were selected using a two-stage statistical sampling process to ensure 
representation across geographic regions and inclusion of a wide range of treatment 
facilities. First, all counties in the U.S. were assigned to one of 10 geographic strata of 
equivalent size, based on population. Next, counties within strata were randomly 
sampled. All privately funded treatment centers in those sampled counties were then 
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enumerated using published directories, yellow pages listings, and survey sampling 
databases. Centers were then sampled proportionately across strata. Over time, centers 
that have closed or declined to participate have been replaced with other eligible private 
centers from within the same geographic stratum, such that we maintain the geographic 
representativeness of the sample and a target sample size of about 400 centers at each 
wave of data collection (Roman & Johnson, 2004). 
Eligibility criteria for centers: Eligible centers were those offering treatment for 
alcohol and drug problems, at a level of care at least equivalent to structured outpatient 
programming as defined by the American Society of Addiction Medicine’s Patient 
Placement Criteria. Counselors in private practice, DUI / driver education programs, 
halfway houses, and programs offering exclusively methadone maintenance services 
were not eligible (a separate survey collected information about these programs). 
Programs with methadone units were eligible if other (non-maintenance) addiction 
treatment services meeting ASAM level of care criteria were available. Additionally, 
because the research design focused on privately funded treatment services available to 
the general public, treatment units based in correctional facilities and those operated by 
the Veteran’s Administration were not eligible (Roman & Johnson, 2004). 
Data collection procedures: Administrators and clinical directors of each 
participating treatment center provided data in face-to-face interviews that were 
conducted between 1995-1996. These interviews were repeated in 1997-1998, 2000-
2001, and 2002-2004. This final wave of data will be utilized for this research, allowing 
	  48	  	  
for an exploration of early adoption of buprenorphine/naloxone (approved for use in 
2002) compared to methadone, a medication that has been available for several decades.  
 Interviews focused on organizational structure, management practices, personnel 
(number and type), case mix, and services offered. A particular focus was the centers’ 
adoption and use of various evidence-based treatment techniques, including 
pharmacotherapies and psychosocial therapies for addiction treatment (Roman & 
Johnson, 2004).  
The NTCS is often used in studies examining the association between 
organizational characteristics of substance abuse treatment programs and the adoption of 
various practices and provision of services (e.g. Abraham, O’Brien, Bride & Roman, 
2011; Abraham & Roman, 2010; Rothrauff, Abraham, Bride & Roman, 2011). Though it 
is a large nationally representative sample, rich in its institutional variables, several 
limitations with regard to this dataset can be anticipated: 
 First, the available data are cross-sectional and therefore any analysis cannot 
include historical trends or changes.  
 Second, the available data include only private substance abuse treatment 
facilities. Therefore, comparing privately funded facilities to publically funded ones is 
not possible. In previous studies this has been a variable of interest (e.g. D’Aunno, 2006; 
Friedmann, Durkin, Lemon, & D’Aunno, 2003; Knudsen et al., 2006). The NTCS 
uniquely defines private centers as those receiving less than 50% of their annual 
operating revenues from government grants or contracts, and collects data on the 
proportion of funding from managed care sources. Therefore, we will use the proportion 
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of managed care funding as a predictor variable. We will also explore themes related to 
funding in our qualitative data. 
 Third, the survey did not include validated scales or other previously used 
measurement for the concepts of interest. Of course, since I am conducting secondary 
data analysis, it is important to note that the survey was not constructed with specific 
goals of theory testing in mind, so not all measurements are theory driven. 
Dealing with missing data: The NTCS is a very long survey conducted often over 
several interviews. It is complex and overall requires several hours to complete. As such, 
missing values occur in several of the variables of interest. Multiple Imputations (MI) for 
handling missing values were performed. Imputation is the substitution of some value for 
the missing values, allowing for complete-case analysis rather than list-wise deletion, 
which can significantly reduce the sample size. Single imputation methods, such as 
imputing with a single arithmetic mean value, are traditional methods for dealing with 
missing values. However, multiple imputation is increasingly being used (Allison, 2002; 
2010; Enders, 2010).  
Multiple imputation is a 3-step process. First, multiple datasets are generated 
according to a specified imputation model. In each generated dataset the missing values 
are replaced with regression-estimated values. Second, data analysis, in which standard 
analytical techniques are performed on each imputed (i.e., completed) dataset to obtain a 
set of data estimates; the obtained estimates are adjusted for missing-data uncertainty 
(variances). Finally, results are pooled from the completed-data analyses into one MI 
dataset. 
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Multiple imputation assumes that the data are at least missing-at-random. Another 
assumption of MI is that variables in the model have a multivariate normal distribution. 
However, the imputation method seems to work well even when this assumption is 
clearly violated (Allison, 2010). Stata 11.0 was used for all MI and statistical analysis. 
Allison (2010) recommends that the imputation model include all the variables 
that are to be included in the regression models to be tested on the imputed dataset. Table 
5.1 summarizes the variables included in the imputation model and details their percent 
of missingness. Allison and (2010) and von-Hippel (2009) both recommend 'transform 
then impute'. Therefore, continuous variables which did not meet the assumption of 
normality were transformed before performing the multiple imputations, though 
normality violations of variables may not pose a serious threat to the multiple imputation 
parameter estimates (Enders, 2010). 
Analysis: Means, standard deviations and frequencies were calculated for all 
variables, and distributions were examined. In all analyses, the assumptions underlying 
the application of all the statistical methods that are used (such as normality) were 
examined, principally through the use of standardized residuals, influence diagnostics, 
and graphical displays. Variables were transformed when appropriate. Logistic regression 
models were used to examine the effects of the correlates described and in the hypotheses 
above operationalized below on the dependent variables. In order to identify the most 
parsimonious model, the significant correlates in each model were retained.  
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Table 5.1  
Summary of Variables Used in the Imputation Model and % of Missingness 
(N=369) 
Variable % missingness 
Currently treat with methadone  0 
Currently treat with buprenorphine/naloxone 0 
Currently provide MAT (methadone or 
buprenorphine/naloxone) 
0 
State licensing 0.3 
JCAHO accreditation 1.1 
CARF accreditation 1.1 
Parent organization medical facility (dummy variable) 0 
Participation in research - ever 1.4 
Use of ASAM to match client with appropriate level of 
care 
0.8 
Use of ASI during intake 0.8 
Active alumni program 0.5 
Proportion of MC funding 20.9 
Impact of managed care arrangements (mean of 17 items 
on a scale of 0-5 each) 
13.3 
Orientation to medical/psychiatric model of addiction (0-5) 0.5 
Proportion of clients with dual diagnosis 26.3 
Proportion of clients who are relapsers 3.3 
Proportion of clients with primary diagnosis of opiate 
dependence or abuse 
5.7 
Proportion of counselors – MA level or higher 20.6 
Proportion of counselors in recovery 19.2 
Knowledge of CTN (0-5) 0.5 
Alumni activity (mean of 6 items on a scale of 0-5 each)* 0.5 
Manager tenure at organization (years) 2.7 
Manager tenure in BH field 0.5 
Age of organization 3.5 
Facility size (# of admissions/FTE's) 10.6 
12-step orientation (mean summary of yes responses to 4 
questions) 
0.3 
Proportion of clients who are women 1.4 
Proportion of women clients who are pregnant 2.7 
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Variables and measures. 
Dependent variables. 
The unit of analysis in this study is substance abuse treatment centers. Using the 
NTCS, provision of medication-assisted treatment is operationalized at the treatment 
center level and is measured dichotomously – does the center provide methadone or 
buprenorphine/naloxone (yes/no). Early adoption of medication-assisted treatment is also 
measured dichotomously via the provision of buprenorphine/naloxone (yes/no), which 
was approved for use in 2002. This wave of the NTCS was collected between 2002 and 
2004, during the first couple of years from the introduction of buprenorphine/naloxone. 
Independent variables. 
The independent variables in this study are the various institutional forces and 
logics operating in the organizational field of substance abuse treatment. I now turn to 
operationalize each group of independent variables in accordance with the hypotheses 
(see also figure 5.1). 
Coercive Factors:  
Data on JCAHO and CARF accreditation was collected (yes/no), and administers 
were asked whether the center was licensed by the state (yes/no).  
Type of parent organization - administrators were asked to report whether parent 
organization was state/county, local, hospital, individual, corporation, religious, 
university, private, board of directors or other type of organization. A dummy variable 
was created for organizations whose parent facility was a hospital (yes/no). 
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Proportion of managed care funding - proportion of managed care funding was 
computed by dividing the amount of funding (in dollars) from managed care sources 
(HMOs, PPOs, POSs) by the total revenue of the center (continuous measure). 
Impact of managed care arrangements - Administrators were asked about the 
impact of managed care on various organizational practices (each on a scale of 0-5). 
Questions included to what extent does managed care: (1) recommend the content of the 
treatment plan (2) change the content of the treatment plan recommended by your staff 
(3) require that communication for authorization of further treatment be conducted with 
the client's primary clinician (4) refuse authorization of further treatment even though 
center staff recommends that treatment continue (5) require written communication by 
members of your staff (6) require efficiency in your center's treatment protocols (7) 
require members of your staff to coordinate care with health care or social service 
providers on behalf of clients (8) require your staff to closely monitor client progress (9) 
require verification of quality assurance procedures (10) require your staff to pay 
attention to matching clients with appropriate level of care (11) require staff awareness of 
effective treatment practices (12) require close monitoring of center's operating costs (13) 
require close monitoring of patient charges (14) require negotiation for provision of 
services (15) require negotiation for patient charges (16) require staff training and 
development, and finally (17) to what extent has managed care led to the development of 
new standard operating procedures in your center. A mean score ranging was calculated 
to measure the level of managed care involvement. 
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Normative Factors:  
Attitudes towards medication-assisted were not measured in the NTCS, and will 
be explored in depth using the qualitative interviews 
The proportions of clients who are relapsers (have been in treatment for their drug 
dependence two or more times), have a primary diagnosis of opiate addiction, and are 
dually diagnosed were also assessed directly in the survey (continuous measure, assessed 
by a direct question in the survey).  
Competing identity logics:  
Administrators were asked how many counselors employed at the center were in 
recovery. Proportions of staff in recovery were calculated by dividing this number by the 
total number of counselors at the center.  
Administrators were asked how many counselors employed at the center held a 
master’s degree or any higher degree. Proportions were calculated by dividing this 
number by the total number of counselors at the center.  
Centers’ emphasis on the 12-step approach is also operationalized at the treatment 
center level. Directors were asked (1) whether their program is based on the 12-step 
model, (2) whether attendance in 12-step meetings during treatment is mandatory, (3) 
whether 12-step meeting were held at the center and (4) whether there is a direct effort to 
link clients with 12-step programs at discharge. A composite score ranging from 0 yes 
responses (low emphasis on 12-step approaches) to 4 yes responses (high emphasis on 
12-step approaches) was compiled. 
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Center’s emphasis on the medical model was assessed directly in the survey (on a 
scale of 0-5). 
Salience of milieus: 
Connections to research – directors were asked if their center has ever participated 
in research (yes/no), director knowledge of the Clinical Trial Network (on a scale of 0-5), 
and use of standardized addiction measures to assess clients’ level of addiction (ASI and 
ASAM).  
Connections to alumni networks – directors were asked whether or not the agency 
has an active alumni program. If the answer was yes, they were asked to what extent (on 
a scale of 0-5) alumni were involved in 6 areas: (1) referring patients, (2) serving as 12-
step sponsors, (3) volunteering, (4) making charitable contributions, (5) serving on the 
board, and (6) lobbying for funding. A mean score was calculated to measure the level of 
activity.  
Embedded Agency: 
 Clinical directors were asked to provide personal background. They were asked 
about their tenure at the center and in the behavioral health field (in years). 
 Administrators were asked to report the age of their center. Size of center was 
operationalized as the number of full time employees. 
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Organizational Correlates of Medication-Assisted Treatment Provision 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Predictors of medication-assisted treatment and early adoption 
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Chapter 6 
Findings 
Chapter Overview 
This chapter presents findings of the study, both qualitative and quantitative. First, in the 
qualitative section, I discuss the main themes that emerged from the interviews. The goal 
of this section is to foster a nuanced discussion of factors that may be salient to 
organizational service provision and adoption of practices in the field of substance abuse 
treatment. In the quantitative section I first present descriptive statistics on the relevant 
dependent and independent variables. I then present a series of logistic regression models 
to examine the extent to which the identified organizational and institutional 
characteristics (independent variables) affect the likelihood of providing medication-
assisted treatment, being early adopters of medication-assisted treatment and providing 
methadone (dependent variables). 
 
Qualitative Findings 
 Thirty face-to-face interviews with managers and directors in substance abuse 
treatment centers between were conducted May 2009 and June 2011. An analysis of the 
content revealed that networks, individual agency and competing ideologies are 
extremely salient factors in service provision and adoption of practices and that these 
factors can either compliment or battle coercive and normative forces. Specifically, much 
attention was paid by interviewees to the coercive and normative forces that play a 
central role in organizational change, while simultaneously stressing the active role of 
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individuals within the organization to promote or hinder change. For heuristic purposes, 
the five central themes presented in the theoretical framework chapter, will be used to 
frame the results. These themes were often complicated by personal attitudes and beliefs. 
 
Coercive institutional forces 
 Coercive forces are associated with the control exerted by funding, licensing and 
parental organizational sources. Almost all of the interviewees pointed to issues of 
funding, licensing and accreditation as forces that hinder service provision. This was 
particularly strong for managed care arrangements. One CEO of a large hospital-based 
program said: 
 
[The drug and alcohol field] has changed considerably. It has gotten much 
more professionalized. Now it’s getting tighter and tighter with 
regulations. [We] have to do a lot more for a lot less… [There are] HMO 
changes and the behavioral health carve outs. All of that stuff has changed 
how we do things … They [licensing and accreditation agencies] are all 
over us. We answer to more people than you can think of. All of them 
have different agendas … None of them line up, which is one of the 
greatest difficulties. JACHO has their set of expectations and state have 
their set of expectations and CBH which is the major HMO for Medicaid 
recipients in Philadelphia have their expectations. It would be nice if the 
three of them would talk occasionally and realize they are asking for the 
same thing. But it doesn’t work that way. Each one of these individuals 
who come with each given agency come with their own expectations and 
their own biases as to what something should look like and how it should 
be written in the treatment plan, how it should look like in the progress 
notes. One person may think it’s completely satisfactory and another 
person may look at it at from a different angle and say it’s completely 
unsatisfactory. So we try to aim for the most stringent of the reviewers but 
we still wind up missing the mark. 
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The program director provided an example (similar examples were provided by several 
other interviewees): 
They [licensing and accreditation people] are stringent about a lot of 
things. Especially how methadone is kept and stored. How it is spent. 
They are specific about a lot of stuff. And it’s really difficult to get them 
[to allow us] to modify [services] or get exceptions if they are seeking 
methadone, that is, requesting opioid replacement therapy, then there are 
very specific rules as to do who can get on the methadone program 
regarding the rate of addiction etc. There are a whole bunch of rules. The 
other services are not so stringent. Somebody can walk in off the street 
and say that they are a cocaine addict, say ‘I want something to use’… In 
all likelihood you can sit there and see what they need recipient and 
probably can get them started [in treatment] and get the process moving.  
 
This example also suggests that client characteristics (not being an opiate addict) may be 
interacting with licensing (a coercive force) to influence certain types of services.  
 Managed care arrangements were discussed by many as hindering service 
provision. One director, whose thoughts were echoed by several other interviews, said:  
[Managed care] was a major problem when it first came in. Because they 
don’t want to pay for anything... When they did decide to carve out 
behavioral health - give it to CBH for Medicaid patients, it has worked 
much more smoothly. A lot of bumps in the beginning, but worked 
smoothly. They pay for designated services of substance but they do not 
cover methadone treatment. They will not cover it at all. And that is, 
unfortunately, an argument that we haven’t been able to win with them.  
 
Another director of a public treatment center added: 
 
I’ve seen that the people that they [managed care firms] are authorizing 
are people who have had a shorter time of addiction. People who are 
chronic substance abusers, they are not letting in treatment, and they are 
the people who are more impaired and more in need. 
 
The last quote, which also supports that client characteristics play a role in service 
provision, was reflected in a number of other interviews. It is interesting to note that the 
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director suggested that managed care arrangements prevent his organization from treating 
clients with more serious issues.  
 A program director at a very large and established private organization described 
how issues with managed care arrangements caused the organization to modify its entire 
structure, also causing changes in the types of clients they treat: 
When I first started here, we had county contracts. We did managed care. 
At that point we were also were defining programs around that. We had a 
short-term stabilization program, because that’s all managed care would 
fund. At some point our leadership team decided that rather than designing 
programs to meet other people’s needs, we were going to design 
treatments to meet the patient’s needs. So then we designed programming. 
It reminds me of the ‘Field of Dreams’ movie – if you build it, they will 
come… So then we switched to a private pay facility. And so our patients 
then choose to pay. And we can offer scholarship dollars in relation to that 
… Our clientele currently are those who can afford it. Previously when we 
had county contracts and things of that nature we were having patients of 
the county that were sent here. 
 
This director suggested that managed care arrangements prevented his organization 
(formally a public one) from treating clients with more serious substance use problems. 
While his organization was not willing to accept the situation and switched to private 
pay, it seems that the new structure also prevents the organization from treating certain 
types of clients – those who cannot afford their services. This supports the notion that 
while managed care is crucial to making services affordable, it is also restrictive. 
 One director discussed issues of funding and managed care particularly in 
reference to medication-assisted treatment. He suggested that different factors might be 
influencing the provision buprenorphine/naloxone and methadone, a point made by many 
other interviewees. Specifically, he suggested that managed care promotes the provision 
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of methadone because it is a cheaper medication, while not giving clients an alternative 
treatment options: 
So, of course, now there is a big move to move to medicated assisted 
treatment … the suboxone people and the methadone people. The 
suboxone people are saying - and it does look to me like it’s a great drug - 
that it is much better for opiate addicts because it’s the blocker … and it’s 
not as addictive as the methadone. So I don’t know why people are 
struggling with switching that off. Now suboxone is very expensive and I 
don’t think Medicare pays for all of it. There must be some financial thing 
to it. But methadone is pretty cheap. The idea of health choices, which is a 
state initiative that PA has to follow, says that each client has the choice. 
These clients clearly do not have a choice and how managed care is 
getting away with it is they are saying ‘well, we are giving them a choice, 
we are telling them you either go on methadone or you don’t go 
anywhere’. Well, that’s not a choice. If the client says openly ‘I don’t want 
methadone’ then they say ‘well, I’m sorry, that’s what we are giving you, 
that’s your choice, we are giving you something’. So it is the genocide. 
I’ve had a lot of parents call me, at least 10 in the last year, parents of 
young heroin or benzodiazepine addicts, I’ve had 2 grandparents call me 
… they went and bought suboxone of the street and detoxed their own 
kids because they didn’t want to go back on methadone. So it is causing 
another kind of unofficial system to go on. 
 
Several interviewees discussed other ways in which managed care affects their 
organization, as exemplified by the following quote. The director of a large methadone 
program, discussing managed care oversight and education requirements, pertaining to 
hiring decisions said: 
[Managed care monitor us] in a couple of different ways. One, the most 
obvious, they come in and say ‘you have service - show us the 
documentation. And you better have the documentation available! ... 
Another way they control level of care is through authorization of 
services... So there is definitely oversight that way. Oversight and control  
… it’s much more obvious with inpatient treatment, hospitalization, 
residential. They are much more stringent than outpatient. Also, I have 
seen that has probably resulted in elevation of the sort of minimum 
education requirements. I can’t say that it has formalized anywhere. …We 
used to be able to hire people with life experience. And they could be 
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counselors with life experience and very little academic training at all… in 
state recovery. Pennsylvania now has very stringent rules. The educational 
requirements and experiential requirements to be called a counselor is a 
minimum bachelor’s degree, preferably a master’s degree. So the folks 
that we used to able bring on board, we can’t bring on board because of 
the supervisory requirements that are imposed upon us. It’s just too 
burdensome. 
 
This last quote also hints at some of the complexities and interactions that might be 
affecting service provision in the field. For example, while managed care might affect 
service provision directly, it is also possible that it interacts with factors such as 
counselor credentials, education and recovery status (competing identity logics) to impact 
service provision indirectly. 
 
Normative institutional forces 
 Normative forces in substance abuse treatment are characterized by managerial 
attitudes that shape the norms associated with service provision, as well as client 
characteristics that shape the standards of care associated with certain types of client 
profiles. Managerial attitudes are the only force I was unable to explore in the 
quantitative data set. Therefore, this section on normative institutional forces is 
comprised of two parts: themes related to client characteristics are followed by a broad 
discussion of managerial attitudes. 
 
 Client characteristics. 
 Interviewees often pointed to the unique or changing needs of their client 
populations, and how these needs often determine the types of services offered and the 
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level of care. They also pointed to changing needs of client population as a catalyst for 
adopting new practices, particularly when those were in line with organizational 
ideology. In addition to clients suffering from opiate abuse as well as clients with dual-
diagnosis, many pointed to HIV status and demographic characteristics of the clients, 
such as age, race, religion and gender as influencing service provision. One director 
discussed his program’s opiate addicted clients: 
We have patients on methadone for a long time who are very low dose and 
they just do not want to detox. Nobody says that they have to go. We have 
to accept people with such high dose that they are a danger to themselves 
and everybody else. We use to have a cap of 80mg of methadone. In 
Philadelphia it’s just not sufficient. So they have done away with caps. A 
lot has changed because everyone was requesting exceptions.  
 
While this quote exemplifies how client needs and desires were instrumental in 
modifying an organizational practice, this next quote, by a director of a women’s 
program, suggests that normative forces have an effect but that they take a back seat to 
organizational ideology. It also suggests that client characteristics might be interacting 
with each other to influence service provision (in this case opiate addiction and gender): 
That program also is a fairly traditional 12-step program. The women's 
treatment plans are all about what steps are you on. We do use methadone 
for maintenance for women who are in pregnancy, but then detox them 
after. 
 
This was not the case in another 12-step oriented program that encounters pregnant 
women who were opiate abusers. Rather than provide a service that is at odds with the 
organizational ideologies, this organization does not accept pregnant women into 
treatment. The program stated: “We don’t accept pregnant women who are on opiates, 
mainly because we don’t do maintenance, and that’s what they need.”  
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 Many other interviewees discussed methadone in the treatment of opiate addicted 
women in general, and pregnant women in particular. Methadone, though often viewed as 
replacing one addictive substance with another, was generally more acceptable for this 
population, even if not adopted in a particular organization.  
 This next quote by another director of a women’s’ program discussed how her 
personal views towards methadone for pregnant women over the years have shaped 
services provision, suggesting that her long term embeddedness in the field might be 
interacting with normative forces to influence service provision.  
We’ve seen a tremendous increase in the number of clients that they are 
forcing on to methadone. But everybody knows that I caused a big hoopla 
in the city when I was working for a women and children’s program - used 
to be straight D&A. It is now a methadone program. Before it turned into a 
total methadone program I was responsible for evaluating face-to-face 
interviews with all the women who were going over there who were on 
methadone. Well, I had a real problem with all this, because most of the 
women who were coming to see me were pregnant, and they were really 
dosed up. So dosed that they could not really participate in the interview, 
nodding out, really out of it on very high doses of methadone - which I 
kept denying them. I said ‘something is wrong here’, I made a big stink 
about it and the medical director over there called me because I said 
‘aren’t they like breaking the law? I don’t think you are allowed to have a 
certain amount of dose.’. Well, I learned a lesson then, too. Because when 
you are pregnant you can be on a very high dose of methadone because 
your fetus takes more of the methadone. I said ‘well, ok, but I think they 
on too high of a dose’. They couldn’t even sit, they were really literally 
nodding out. But we admitted them and what happened was I was trying to 
stop, I was resistant to the organization turning into a methadone and 
children’s program, but I lost that fight because I was the only one. 
Nobody else cared. So here they are now - a methadone women and 
children’s program. But I hired some of the people who worked there, too 
and they said what happens to those babies afterwards, it’s inhumane. 
 
This director, who was unable to change her former organization’s practices based on her 
experience and beliefs, mentioned it was the main reason she left that organization. She 
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chose to work for an organization that does not treat pregnant opiate addicts with 
methadone. 
 Another director of a therapeutic community pointed to the complex relationship 
between client characteristics, funding and organizational philosophy: 
Our philosophy is abstinence. We only have one program that is a women 
and children program that takes chronically mentally ill women and their 
children. The only way we were able to get this grant is that we had to sort 
of get in bed with them and say – ok, if you have a methadone woman, we 
agree that we will take one or two of them. But other than that we don’t 
have maintenance, nothing like that because the concepts and just the 
values of the therapeutic community are abstinence, drug-free. 
 
Another director of a program for adolescents explained how working with adolescents 
has led to treatment practices that are not necessarily in line with the organizational 
ideology, at least initially: 
Our company is an abstinence-based program. ... That being said, you deal 
with adolescents, you have no option but harm reduction at times … When 
you are moving somebody through the stages of change, and then they 
come in not ready for abstinence and you have to then prepare them for an 
IOP and meet with them individually. So you are trying to reduce their 
risk while moving them along. 
 
Therefore, while encountering and treating pregnant women might facilitate the adoption 
of methadone by some programs, long-term methadone maintenance for women who are 
not pregnant remains an unacceptable treatment option for this organization because the 
practice is seen to be at odds with their 12-step ideology. Similarly, encountering and 
treating adolescents might facilitate harm reduction practices in an abstinence-based 
program. 
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 Race and religion were also described by several interviewees to affect service 
provision. One director pointed to disparities in service provision for Latino clients: 
We’re smack in the Latino community here … a mono-lingual person, 
their choices are way limited to where I can send them, as oppose to 
somebody who can get by speaking English. And [even when they get 
treatment] the services then differ in terms of the quality. Shouldn’t be that 
way, but it’s the way it is. Now we are starting to look at that whole 
disparity issue, which affects our approach to public health…. So there is a 
whole disparity going around in terms of the amount of services that we 
provide.  
 
Another director at a large private organization pointed to clients’ religious and cultural 
needs as promoting service provision, while giving the example of orthodox Jews: 
I think one of the things that absolutely sets [my organization] apart…is 
our pastoral care – the spiritual side of things is gigantic. It’s a gigantic 
gap in most using drug addicts’ life, and alcoholics’ life. And it’s 
something that needs to be addressed in treatment and in recovery. And 
our pastoral services ability to meet [our clients] in a meaningful spiritual 
way, that age group, very difficult to do – they do it beautifully. It’s a huge 
part of what we do. In fact, one thing we do as well as any treatment 
center that’s not affiliated with a specific religion. For instance, orthodox 
Jews choose this organization … for a number of reasons. We understand 
Judaism and what it means to be a recovering Jew. We have a Rabbi on 
staff ... we have any number of minority kids, and especially minority 
religion, Jewish being the most well represented. So I think it’s not 
atypical to have 10-15% Jewish clients, and a decent percentage of them 
even orthodox. Kosher kitchen, understanding of the orthodox tradition, 
needing to sleep parents close to campus or even on campus during family 
weekend so that they can observe the Sabbath. I think you are going to 
find that [here], always a willingness to have that level of customer 
service. If you ask we are going to try and get it don’t. We know our 
limit’s, but if we can we are going to get it done. So a kid coming in, a 
Jewish kid who is not Kosher and not orthodox, a lot easier perhaps. 
We’re still going to offer Temple, still going to offer Rabbi services, but 
they might not be as invested. But a true orthodox, who needs all the other 
stuff that we have, we are going to get their needs met, too.  
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Many of the directors discussed clients with dual-diagnosis, and how the field in general 
has evolved to accommodate them, via the recent merging of substance abuse and mental 
health. One director described how changing practices in his organization following the 
merging are also impacted by demands from funders: 
… You can’t really separate them (SA and MH) completely because all of 
our clients have some kind of MH issues, even if it's just depression. ... 
However, the other thing that sometimes people don’t realize is that there 
is a huge variety in dual-diagnosis clients, so you have dual diagnosis that 
are primarily MH and their D&A is secondary, you have clients that are 
the opposite – the D&A is primary and the MH is secondary, and then you 
have the in-between. So sometimes program funders want us to be able to 
treat everybody and say ‘well, you are dual diagnosis, you should be able 
to handle somebody with MH’, and that is just unrealistic because certain 
types of disorders have to be treated in a different way. It’s like mixing 
apples and oranges. These are the issues for this population, even though 
they have a common thread - they have dual diagnosis and they have more 
than one issue – it doesn’t mean that they are all in the same boat and they 
require very specialized treatment. But I think that it’s kind of unrealistic 
to expect that you can deal with one and not the other or deal with them 
completely separately. 
 
She was not the only one who described some of the issues arising from providing 
integrated services. Another director states:  
Our day IOP is always a dual diagnosis because if they [clients] are not 
working, it’s usually is a symptom [that they have] mental health issues. If 
someone is coming in with bipolar, major depression, generalized anxiety 
disorder – they will have a life counseling clinician while they are in IOP, 
and their psychiatrist. So we use all these to become more integrated 
although we don’t have a really sophisticated model. We are working on 
that. We are trying to figure a way that we can work with more integrated 
clients. And we are published as a dual diagnosis agency. And we’re not. 
 
The last two quotes, by directors discussing the merging of substance abuse and mental 
health, can also exemplify competing identities in the field, suggesting again that multiple 
factors interact to influence the types of services offered.  
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 Managerial attitudes. 
 As mentioned above, managerial attitudes towards medication-assisted treatment 
were not assessed in the quantitative dataset, in which the unit of analysis is the 
organization. However, this theme was explored in the interviews. Attitudes of 
interviewees were more often than not in line with the organizational philosophy of their 
organization. Methadone was viewed by many of the interviewees as part of the harm 
reduction movement, and entirely contradictory to 12-step, abstinence-based approaches. 
Several described it as replacing 'one addiction with another'. Attitudes towards 
buprenorphine/naloxone, on the other hand, were more favorable and, when discussed, it 
was mostly viewed as a medication for the treatment of addiction. 
 One director in a 12-step based program (who used the terms methadone and 
harm reduction interchangeably throughout the interview) said: 
I’ve never heard it to work, for me I just can’t imagine that it would work. 
I just think it’s a rationalization for people to continue their use. To tell 
you the truth, I think that some people who promote harm reduction in 
those cases, probably they are heavy drinkers. That’s my theory about it 
and saying they don’t want to tell somebody else ‘give it up completely’ 
because they don’t want to give it up completely because they can’t 
imagine doing it themselves. And I’m not saying that in other fields its 
bad, like HIV does a lot of HR and that’s a whole different story, but when 
you are dealing with addiction I just don’t think it makes any sense. 
 
Another director who also used the terms interchangeably expressed a similar view: 
Personally I don’t subscribe to that. I don’t believe in the harm reduction, 
mainly because I think to some degree it negates the disease concept, and I 
believe in the disease concept and the medical aspect of it. And so I 
believe you can put the symptoms in remission. My own take. At the same 
time, I know it exists. I respect people who do that, and I do believe there 
are some patients that just like methadone, although I personally would 
not work in a methadone clinic.  
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A third director said: 
I believe personally that [harm reduction] is a dangerous philosophy and I 
also believe that that kind of stuff – harm reduction or moderation 
management or any number of those things – they are beautiful marketing 
tools for the addicted brain, which is always looking for an easier out. 
When you are a drug addict, when you are an alcoholic, that’s a great 
marketing tool. If I’m a person considering treatment or if I’m getting 
pressed into treatment, harm reduction – that’s beautiful. That’s where I 
want to go to rehab. Because that model falls right into line with my 
addictive thinking pattern. So I espouse … a 12-step philosophy and an 
abstinence-based model that I am completely comfortable with, and 
frankly if an employee comes here, and is not comfortable with that, or if 
they come to interview, it’s not going to work for them here. 
 
These three quotes, reflected ideas brought up in several other interviews, equate 
methadone provision with harm reduction, which was not viewed favorable by many 
interviewees. Another director, whose organization has adopted buprenorphine/naloxone 
for detoxification went further to criticize the manner in which organizations provide 
methadone to their clients, especially their younger clients: 
I think Suboxone is probably better [than methadone]. I have, in all my 
years of working with addicts, have never found anybody to do well on 
methadone, because the methadone clinics in themselves, just the 
environment and the atmosphere has so many addicted things going on – 
people are dealing drugs, people are using – there really isn’t any clinical 
treatment going on in the methadone programs and people just go in to get 
their juice and leave so it perpetuates the dependency and real unhealthy 
behavior. And they put people on such a dose, they start them and they go 
up such a high dose that people can’t just stop going, they have to keep 
going. And they bring them down very, very slowly – they pump them up 
really quickly and bring them down slowly. But there is nobody who is 
really challenging them, nobody who is really evaluating them, no one 
really doing that because it’s a big money maker and they are very well 
protected by the city. So nobody has really exposed really what’s going 
on. We’ve had a lot of staff that has come here, who works for us now, 
who worked in methadone programs and they tell you stories that are like 
horror stories of young kids. [I was told] that in this one methadone 
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program … they are seeing younger and younger and younger kids – 18, 
19 year old kids are on high dosages of methadone. And when they are 
done [with treatment], and they keep getting the methadone, they are 
getting high and they are young, they are not even heroin addicts, they are 
benzodiazepine addicts, so any opiate, benzodiazepine, Percocet, anything 
like that, they are throwing everybody on methadone. So I’m not a pro-
methadone person, even though I have a friend, who has been a 
methadone doctor forever, and she’s a good friend of mine. We’ve had 
some heavy conversations about it. But in the purest sense if you talk to 
people, in the purest sense of what they think should happen, if it really 
did happen that way – then, ok, it would be great, but it doesn’t. In reality, 
it doesn’t happen that way. There is a lot of riffraff. 
 
This suggests that views towards buprenorphine/naloxone and methadone, though both 
medication-assisted treatment might be quite different and that it is possible that different 
factors influence the adoption of each. This statement also lends support to the hypothesis 
that certain characteristics of clients served by the organization might be influencing the 
types of services provided, in this case age.  The same director provided an example of 
how his views towards methadone for younger clients played out to determine a course of 
treatment: 
There is one psychiatrist … who I’ve worked with for many, many years... 
We just had a 20-year old kid, she just turned 20. He said ‘look, … she 
can only go to methadone’. She’s been using heroin for 5 years, been in 
and out. Well, I said to him ‘she was an adolescent when she started 
using’. We have to keep everything in perspective. It’s not like an adult 
who’s a chronic user, this is a kid who was in high school. And I said to 
him ‘give us a chance we will put her on suboxone here, let’s see how that 
works’. He said ‘ok, I’ll do it’. So we had her here, she stayed on 
suboxone, she completed treatment, he was quite surprised because she 
runs every time, but people who are on methadone there is nothing else 
happening, I mean, that’s all they are doing is getting dosed every day. 
There is nothing else, nobody is dealing with any of their other issues and 
addiction is a symptom. If you don’t deal with everything else, people are 
going to keep using. If it was that easy that we would just give everyone a 
dose that the substance abuse field would be done. We wouldn’t be as big 
as we are. 
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A director of a 12-step based women’s program shared that her attitude is to ‘be open to 
what works’ and that she often questions her organizations’ practices. She said: 
Sometimes I will question [why we don’t have a longer detox]. … And 
then whenever I see any kind of article that looks at longer detoxing I send 
it over to the medical director ... We have family education and patient 
family members have to go through the family education day before they 
can come visit their family members. And so there is a rule that if the 
person … looks like they are high or actively, or if the patient tells us that 
they are actively using then they are not allowed to come in for the family 
education. I can see how that somewhat makes sense …Their more likely 
than someone else to you know try to sneak drugs and stuff. But one of the 
counselors said that so and so boyfriend shouldn’t come in because he's on 
methadone. And I hit the roof! He’s taking a legal medication. He’s taking 
it as directed! Is there any evidence that he’s abusing it?! [I told them] 
Lets just pretend its insulin and that's how I [got him in] … My feeling is 
that you can find a way to manage without medication is better than with 
medication because medication is always going to give you side effects. 
… but not everybody can do that. Some people need insulin, their diabetes 
is just so whacky that they can’t control it with diet and exercise, and 
that’s how I explain it to the staff. And it’s wrong to penalize and to 
stigmatize those people.  
 
Her explanation, which was also given by several other interviewees, introduces the 
diffusion of the medical model into the field. While some of the interviewees stressed 
their support of this model, others were open to it, yet preferred to leave decision-making 
to medical professionals. For instance, one director, who has recently entered the 
treatment field, admitted her lack of knowledge: 
He had the modality that it’s just safer to be on it forever. So I would give 
him clients, and he’d have no reason to taper them, to take them off. I 
don’t really know what to do with suboxone clients, if it’s safe to keep 
them on. Parents ask me ‘what do you think? How long should they be on 
it?’ and I say ‘it’s up to your doctor’. I’m going to stay out of that one. I 
don’t know. 
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Another director shared his attitudes towards methadone and buprenorphine/naloxone, 
suggesting that attitudes might be influenced by knowledge of research in the field:  
I have thought that it is safer to stay on [suboxone]. If it’s going to keep 
you away from smoking or blowing or using oxi, than stay on it. 
Especially, I have a client that’s in his 60’s. Tapering him off suboxone 
right now, he’s only on like a tab and a half a day, if it’s going to keep him 
away from Heroin then I’m comfortable with it. But we also have clients 
that do the dance. You know, who are getting high, using the suboxone for 
the buprenorphine/naloxone effect and then those who are crushing and 
injecting it or selling it because the street market value is so high. … I also 
think there are some side effects to any drug. There’s urinary retention, 
problems with constipation, definitely sexual side effects with suboxone, 
like any other anti-depressant. I’m mixed about it. With methadone, my 
only fear with that is people, places and things. It’s so much easier to 
abuse. For every motivated client there are 10 who aren’t, but I don’t have 
a whole lot of experience with methadone. But I just know that would be a 
fear of mine. You know, what kind of care you get. So I’m as much for it 
as I am against it, I guess. I’m not really against it, I need it. 
 
A CEO of an organization who has provided methadone maintenance for years expressed 
very favorable attitudes towards medication-assisted treatment and talked about how 
years ago he was able to get his clients treatment in another organization that was initially 
unwilling to accept them: 
The guy who is the head of [another organization]… We used to have 
these knockdowns, when we got to meetings we get into these huge fights 
about methadone vs. drug free [treatment]. Now they take patients with 
methadone, they are a little more open to it, but still, these communities 
really do not like methadone clinics. 
 
Another director, who has been in the field for many years, discussed how his views have 
changed based on a newfound understanding of the disease model. He went on to 
criticize drug-free settings that are not open to incorporating medications of any kind in 
treatment: 
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I didn’t really truly accept the disease concept until like 1995. That was 
my own personal issue – there IS brain chemistry here involved, and that’s 
why this person isn’t getting this. It was never a moralistic issue with me, I 
can say that, I wasn’t on that side of the fence. But I was ‘this person isn’t 
doing anything to help themselves’ and I think that’s part of the disease 
itself. So (in 1995) I really got an open mind and started looking at why 
medication is important and why therapy is important. I don’t think you 
can be effective if you do one OR the other. There are some programs, I 
won’t name them, but there are programs around that believe in the [drug-
free) therapeutic community and they beat stuff into kids… It’s funny 
because there’s still a perception in our communities regarding 
medication, and that if you take medication you are bad or you’re weak. 
We’ve been trying to squash that stereotype by working with our families 
and getting them to say ‘just like a diabetic’. A diabetic has to take insulin. 
You don’t call them weak or bad. So we really work with the disease 
model to get them to understand that there is brain chemistry involved 
here and that’s the way it is. 
 
In sum, it seems managerial attitudes towards medication-assisted treatment are tied to 
controversy in the larger institutional field between the 12-step abstinence-based 
orientation and the medical orientation. Also, while many interviewees equated 
methadone maintenance with harm reduction (not viewed favorably by many regardless 
of their personal definition of the term), this was less often the case when discussing 
buprenorphine/naloxone.  
 
Competing identity logics 
 Often different sets of organizational actors adhere to different identities and the 
ideologies associated with them. As motioned above, a prevalent theme that was brought 
up and explored in depth was ideological clashes within the field of substance abuse 
treatment. In particular, interviewees discussed conflicts based on the merging of the 
more traditional abstinence/ 12-step /AA model service providers with a drug and alcohol 
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background (often in recovery) with the medical orientation of the people coming into 
substance abuse from the mental health field (often with a higher education). 
 A clinical director of a program at a large organization discussed recovery status 
and education among clinicians and counselors. He disclosed that he was both in 
recovery and had a master’s degree, which was not common in his organization. He 
suggested that while many counselors in recovery also have degrees (mostly bachelors), 
there are philosophical differences between those who are in recovery and those who are 
not, that might be influencing the services they provide: 
There are a lot of people that are in recovery. Depending on what position, 
you could have as many as 50% in recovery … there are some recovering 
folks certainly with bachelor’s degrees, and even a few more with masters. 
I think if you come to work here, strictly without “formal education” but 
through 12-step and recovery, you’re going to have your own set of ideals 
that are going to have to intertwine clinically with some of the ideals that 
perhaps psychology, MSW might bring, that are non-recovering people 
with those degrees. So, I think there are some differences in expectation, 
and some philosophical differences in how you might address a certain 
behavioral symptom, and how you might intervene on said behavioral 
symptom. There might be some differences between how a recovering 
person would do that without an education, a psychology or social work or 
counseling degree, and how someone with a degree and no recovery might 
interact. 
 
Another director gave an example of how people who have been through 12-step 
programs and are in recovery have a different focus in treatment that people with 
professional backgrounds: 
Mainly, 12-step is a lot more didactic. And typically someone who comes 
from a more clinical psycho-social work background they may 
incorporate, try and create more of a group therapy setting, where they are 
using psychodrama, empty chairs techniques, different group activities, 
having a big array of strategies. ... So I kind of see a lot more process 
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focused, sometimes with the traditional clinical background, whereas 
without it it’s a lot more client talking to clinician.  
 
One director of a program for youth explained that it 'used to be us (i.e. substance abuse 
treatment) and them (mental health treatment)'. He went on to elaborate: 
To me substance abuse is a brain issue. Mental health –also a brain issue. 
You can’t have it both ways. You can’t say I’m an addict or an alcoholic 
and I don’t have mental health problems. We find out when we really sit 
down and look, most of the people that we deal with begin to use drugs or 
alcohol for emotional reasons. It is a crutch, it either calms or develops a 
part of them that they need for stability. … The part that I don’t get. Well I 
do get it, because all the funding happens and that’s why people want 
substance abuse and mental health to stay separate. The D&A folks say ‘if 
we merge the mental health folks will take all our dollars’ the mental 
health people say ‘well, those D&A people are too concrete’. But the one 
thing, and I came from the substance abuse side, that the mental health 
people have over the substance abuse people: substance abuse people 
expect you to go to treatment and get better immediately. Mental health 
people have it in their minds that you are a client for life. And that’s what 
we, the D&a side need to move to …  it really is archaic, because the fact 
of the matter is it’s chicken and the egg – what came first? The mental 
health and then the substance abuse? It doesn’t matter, you treat them 
simultaneously! 
 
A director of a methadone program discussed some of the challenges to the blending 
together of traditional substance abuse and mental health, and how it can affect many 
aspects of the organizational structure. He also pointed to a possible solution, via hiring 
of new personnel that are ‘dually-oriented’: 
It’s been very, very hard. And so there have been a lot of failures on trying 
integrate them. … We can force people to work together, but then they 
come up with ways ‘we are going to separate the waiting room ... all the 
drug and alcohol people will be in this wing and we’ll be in the other 
wing. And that just naturally happens. They naturally kept away from each 
other, they naturally had separate staff meetings. We would try to combine 
the beds and they would still sit apart from one another and there was a lot 
of gap(?) even at Christmas parties, holiday parties, they would not 
mingle. … So we hire new people and we bring in people who do both. 
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We hire them immediately to take on both. It’s kind of hard to take the old 
school drug and alcohol person and their biases and it’s usually around the 
AA model, abstinence only. There is nothing else and they can be working 
with a bipolar and never refer to a doctor because you don’t take drugs. 
You just don’t take drugs. We want to get passed that but it’s hard. … I 
am not going to change them. But we’ve been very successful in bringing 
in and hiring new people. We ask ‘what's your experience with mental 
health, what's your experience with drug and alcohol?’ … They are less 
prevalent to be in recovery themselves... they get both (the substance 
abuse and the mental health) and they want to work for both. So they’ll 
see individuals for mental health and they will also be able to run a drug 
and alcohol group. That’s been successful. I mean we don’t know what 
percentage… Probably a third of our organization consists of those people. 
I can see that over the years it’s went up from zero up to a third and as we 
hire, and the old people retires or those who are part time, we are only 
bringing in people who will integrate stuff. 
 
Another director added, who disclosed his recovery status and described himself as 
adhering to the ‘old school 12-step model’ said: 
Personally I struggle sometimes. It’s different work, it’s a different way of 
looking at things. The downside to this whole co-occurring movement is 
it’s great to diagnose that someone has depression, but people are still 
foggy. If they don’t stop drinking, an you’re just going to take and 
approach to treat the depression, you’re not going to have good outcomes 
…  So it’s an interesting phenomenon that’s happening. What I’ve always 
worried about from a D&A standpoint is in behavioral health D&A has 
systemically always been slow. If you look at [the director of one of our 
other branches], he has a mental health background. … A lot of times has 
a blind side to some of the addictions stuff and he admits it openly. He’ll 
talk with me or [our CEO] about it and say ‘well, what do you think about 
this?’ ‘I have some real concerns here philosophically about how that 
might affect the way that we do things.’ … I kind of look at my role as 
protecting some of the old school stuff, but being open to the new ideas, 
and how do you make that merge. ... So what I want to make sure the 
D&A component doesn’t get lost is if somebody is doing a co-occurring 
group where mental health is more the focus. … And I think some people 
are purely mental health and they miss the D&A piece or they don’t want 
to go there all together, or they have some outer counter-transference 
going on.  
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Several directors pointed to academic training as lagging behind changes in the field, as 
exemplified by this next quote: 
I think the combination of the two - that merging - has been beneficial. 
Frankly, I am not sure though that the educational arena has caught up to 
that. And what I mean by that is - I am responsible for a lot of hiring of 
staff. And I find that people depending on what school they have gone to 
have a different turbulence. They either still looking at a patient through a 
MH lens because that how they have been trained or they are looking at 
them through an addiction lens because that is how they have been trained. 
I find it rare that someone just coming out of school and kind of have that 
full broad picture. 
 
In sum, while most directors acknowledged that being in recovery and belonging to the 
‘old-school traditional AA model’ and coming from a mental health background are not 
mutually exclusive (or exhaustive of people’s orientations in the field), it seems views 
differed on which background had more influence on service provision. This was 
particularly ambiguous since it was noted that many people who are in recovery went 
back to school to get their credentials and/or degrees (often because of demands by 
licensing and accreditation agencies as well as managed care firms). 
 
Salience of milieus 
 Organizational actors belong to networks and milieus that are marked by 
particular cultural practices and beliefs. Knowledge of current research and evidence-
based practices was often mentioned as a factor that affects service provision in general 
and adoption of new practices in particular. This was particularly true for organizations 
whose directors were affiliated with TRI, who helped facilitate the interviews. One 
director of a methadone maintenance program simply stated ‘the research has been very 
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clear that to artificially impose a low dose [of methadone] just doesn’t work. So now it’s 
different.’  
 Another director discussed large-scale changes both in the field and for his 
organization that he believes can be largely attributed to what research milieus share with 
organizations: 
… ‘meeting the client we’re he’s at’, is the biggest change I’ve seen from 
when I’ve started in the field 25 years ago. I think we made a lot of 
mistakes early on in D&A. It was very confronted, and more about tearing 
down the ego. …I don’t think back in those days we took into account that 
people are individuals, there personalities are individual, and so is what 
works. You can’t always go cookie cutter. That might be better for the 
organization than it was for the client. TRI has been responsible, I keep up 
on their research and stuff. Trying to talk people into more a disease 
recovery model, if you relapsed 25 years ago it was like you discharged 
the client. … This is something that I found fascinating – we changed our 
model because of it: when we first started out, [our program was] 5 nights 
a week, 4 hours a night. And then one of the first rounds of TRI research 
they found that it’s more important to have contact with the center, but it 
doesn’t have to be 5 times a week. After that first month, it could be twice 
a week, or once a week, or at the 12-18 months it could be once a month – 
people checking in – and outcomes don’t change that much. I found that 
fascinating and have taken that whole mentality. When people come in 
now, it’s not like they are here for mental illness anymore, they look at it 
like ‘you can do a course of treatment, but keep in touch and stop in, and 
call us before you relapse.’ And you can do that, and I think it really 
makes a difference. 
 
One director discussed how methadone has been shown to be effective in numerous 
studies, yet is not widely adopted. His point also lends support to the suggestions in 
previous sections that ideological conflicts may hinder the adoption of practices and that 
methadone is not compatible with abstinence-based approaches to treatment:  
I think the current administration of the behavioral health is really trying 
to bring methadone in as part of just another vein of treatment. I think 
there is much more acceptance. But you have to realize in this field many 
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of the basics were established early by the national council on alcohol. 
The 12 step and only AA, abstinence all the way. And methadone is 
perceived as just another drug that they are abusing. So even narcotic 
addicts who go to narcotics anonymous don’t necessarily accept 
methadone.  
 
A director of an organization that offers a needle exchange program discussed how his 
organization tries to use research to lift the ban on needle exchange, unsuccessfully.  
We’re fighting, trying to get the federal ban lifted from funding syringe 
exchange. Because there is a federal ban that doesn’t let us use federal 
fund to actually fund a syringe exchange. We can fund ancillary services 
to it, but not the actual exchange. We can’t buy syringes with federal 
money. We think we are close to getting the language lifted. That’s all 
about the science at this particular point. And in Philadelphia it makes a 
lot of sense, because, you’re spending 7 cents a syringe. It’s $200,000 to 
treat 1 person with HIV a year. It’s just common sense. It makes a huge 
amount of good sense, even from a financial perspective, which is an 
argument that we get to make. Never mind the health stuff. People in 
government are interested – spend a dime rather than the $200,000 you are 
going to spend. That’s what it’s come down to, so I do think we’re at a 
point where thanks to research we can make these kinds of valid 
arguments… You know, they are supportive of us for the most part, they 
hear it, but it’s politics. And that’s the thing that floored me. For the most 
part, people want to do the right thing. In our political system, our 
politicians want to do the right thing, but they also want to stay in office. 
And so we have to figure out ways to help them do that so that they 
support us.  
Several others also argued that research findings could be a catalyst for organizational 
change, as long as they do not clash with prevalent ideologies in the field or societal 
values. One director described the process his organization goes through before 
disseminating a new practice. He clearly stated that a new practice would not be adopted 
if it is perceived to be at odds with the organizations treatment philosophy, even if there 
was ample research to support it, giving the example of harm reduction: 
Typically our process here when we get new information we disseminate 
it to our clinical oversight team, and it gets discussed and debated and that 
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sort of thing. To determine first and foremost if it fit’s into our philosophy 
of treatment, and then if is there a lot of research that backs this up vs. a 
on- time thing. And so once it goes to clinical oversight, it’s debated and 
then decided whether or not we are going to use it or not use it, and then it 
gets disseminated to all staff… I know harm reduction exists ... There may 
be all this research with harm reduction, [but] it doesn’t fit into our 
philosophy of treatment, and therefore it would not be disseminated. 
 
Several of the organizations whose directors were interviewed mentioned they employ 
alumni (from their own program) and that many alumni serve on their boards. A couple 
of the directors pointed to alumni as being instrumental to organizational practices. In one 
organization, a director stated:  
If it’s an organizational decision, many times involved is our leadership 
team, with input from board members, our board of directors. Our 
strategic planning process also involves some of our referrals, some of our 
employees and some of our former patients. Our main referral source is 
our alumni…. When individuals leave [treatment], they have to have a 
continuing care plan. So that could be us referring to an outpatient 
therapist, a marriage and family therapist, a halfway house, whatever they 
need following their stay here. 
 
She later attributed this continuing care plan to lessons learned from former patients. 
Another director, while discussing where he gets his information, mentioned that research 
is important but that the most significant knowledge about that field and what works 
comes from their alumni: 
I get it [my information] from people that know the field. Colleagues, 
people I meet at a conference for instance. Families ask for it. It’s not 
atypical for a family to say ‘hey, this kid can’t come home, we can’t do it, 
the kid can’t do it, what’s out there?’ And we have people that research, 
we have people that travel to different places and look around, ask the 
right questions. We have people who come here and tell us about their 
stuff, their place. But the biggest single person that speaks to us, or back to 
us is our alumni – ‘here’s what we did after [we left treatment here], 
here’s what works for us, here’s what was lacking’. Our alumni tell us, 
and keep us in the know. 
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Embedded agency 
 Institutional logics scholars contend that organizational actors and organizations, 
embedded in organizations and institutional fields, have the ability to shape these 
processes themselves. Accordingly, in this study, almost all of the interviewees discussed 
how they found themselves in substance abuse treatment. Half of them disclosed that they 
were in recovery themselves and many of them have been in the field for at least 20 
years. A central theme that emerged was how their personal experience and long tenure 
(which is often accompanied by many personal and professional connections) shape their 
attitudes on one hand, and provide them with opportunities and leverage to affect 
treatment and service provision on the other hand. One director said:  
When you’re in D&A it’s kind of a knit community, so when you open up 
a new center I just kind of use my name, go in there, make connections… 
I’ve been in personal recovery 27 years so a lot of people know me from 
NA, AA. … I have families, they call, I treated their son or daughter years 
ago [another organization]. I’ll get back to them and say I don’t work there 
anymore clinically, but I can put you in touch with the manager down 
there. Or if they tell me a situation, I’ll say X might work better with your 
son because what his personality and specialty is. So that’s what they do. 
And I think it’s from being an old head, from being around so long. 
 
One director discussed how his organization’s medical director stood between him and 
getting a new drug approved for use at his organization.  
So our medical director is really not impressed with [a new drug for 
alcohol addiction]… [He says to me] 'I read the report …, it just reduces 
alcohol usage, it doesn't stop it'. … It's not supposed to stop it! It's 
supposed to help the patient think before taking another drink. It's 
supposed to be used as an aid, but he talked to [our CEO] about it and 
[told him] he's not impressed. So no new medication here.  
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Another director discussed how she established a program for women. Following her 
own recovery and years of professional experience, she realized that many women had 
unmet needs: 
So about 15 years ago, I realized that there was a need for co-occurring 
treatment for women because back then D&A and mental health were 
separated and there were 2 pots of money. I really wanted to create a 
program … were I used to work, that would serve women who had co-
occurring disorders, because it was a big treatment gap back then. … 
When I first came to [this organization], it wasn’t the program it is now. 
It’s been 15 years, but I’ve been able to create into something that I felt 
that women need. 
 
These quotes, which also touch upon the merging of substance abuse and mental health, 
the influence of research in the field and the coercive nature of various funding streams 
exemplify how embeddedness of individuals in organizations and institutional fields 
interacts with other forces that are at play to influence service provision and adoption of 
innovation. 
 Similarly, directors of older and larger organizations talked about how their 
organizations were able to resist certain changes in the field while promoting others. One 
director of an old and established private treatment center talked about how his 
organization was one of the pioneers in bringing in mental health aspects into treatment 
with adolescents, which caused many employees who had a traditional substance abuse 
background to quit: 
So at [this organization] we decided we were going to be at the forefront 
of offering a new kind of rehab services, a transition, so that we’re not 
calling it D&A rehab. That we really were providing some real therapy to 
kids, figuring out what was going on, that drug use is one of the things 
that’s going on, but it’s not everything that’s going on, and then really 
combining that, moving that on… So we brought it mental health. It was 
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difficult because it was a really AA/NA model, they were saying to kids 
‘you can’t follow this rule, you’re out’. And I never understood that in 
treatment anyway, part of treatment is picking up again. That’s just part of 
it. So to kick somebody out for using, doesn’t make sense to me, because 
that’s why they are in the program in the first place. So we had to begin to 
retrain staff. I would say that 80% of that staff was gone …  [in] 5 years. 
And that’s because they were traditionalists, and much to their credit, 
some people came up to me and said ‘this is not what I signed on for. You 
have a different model and I’m going to leave because I can’t support 
that.’ And then some people left in not so supportive ways. 
 
A director of a center that provides needle exchange services discussed how his 
organization was able to use being kicked out of a neighborhood to make leeway on 
another project. He attributed it to the fact that his organization, though controversial, is 
considered well established and carries weight in the city:  
We were having a little bit of trouble a couple of years ago with one of the 
sites we drive vans out to. In one of the sites, people in the neighborhood 
were saying ‘your people litter, they use and then litter, and we have all of 
these needles all over the place and it’s not safe’. So they told the city 
about it, and the city said we had to do something about it and we said ‘we 
could, but by the way you guys are impeding any kind of progress that we 
want to make in terms of getting people in when they are ready to go in.’ 
Because that’s sort of the way they sell syringe exchange to the 
community is ‘this is the bridge to getting people into treatment’. And we 
were able to set up a project where they didn’t take the ID [before 
providing treatment]. We did all of that [bureaucratic] stuff secondary, 
after the person was in. So in 3 months, 47 people got in, where 3 months 
earlier we got only 7 people in, because we would have to go do the ID 
stuff sorted out first. This way we were doing all of that stuff afterwards. 
They were already in a bed [being treated]. And then we would send them 
to the different places that they needed. 
 
Other directors described how the fact that their organization is well established and 
respected, has allowed it to avoid providing services that are not in line with their 
traditional treatment philosophy. For instance, one director of a very large and old private 
facility discussed how the organizational philosophy influences service provision and 
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hiring decisions: 
I am comfortable and in line with [my organization’s] philosophy, which 
is an abstinence-based model where it’s understood that harm reduction, 
although out there, is dangerous. … The organization espouses a 12-step 
philosophy and an abstinence-based model … frankly if an employee 
comes here, and is not comfortable with that, or if they come to interview, 
it’s not going to work for them here. They are going to cross 
philosophically what we are trying do, and it’s not going to work. 
 
These last few quotes suggest that embeddedness of organizations in the institutional 
field might be interacting with other factors to influence treatment. 
 
Summary 
 Analysis of the interviews points to the salience of many factors that may promote 
or hinder service provision and the adoption of new practices in substance abuse 
treatment. Though these factors can be discussed using the conceptual framework 
presented in this thesis, it is evident that they often interact and that the lines are often 
blurred. For instance, while managed care (a coercive institutional force) might affect 
service provision directly, it is also possible that it interacts with factors such as 
counselor credentials, education and recovery status (competing identity logics) to impact 
service provision indirectly. It is also possible that managerial attitudes and 
embeddedness in the field might be interacting with normative forces to influence service 
provision. Furthermore, it seems that some services and practices are adopted faster and 
more effectively. These are often practices that are evidence-based, less controversial and 
go hand in hand with the treatment philosophy of the organization, its leadership and 
societal values. 
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 Results also point to several other variables that might be influencing services. 
For example, while the literature reviewed above suggested that service provision is 
influenced by proportions of opiate addicts, dual-diagnosis clients and relapsers, 
interviewees pointed to the importance of demographic factors such as gender, pregnancy 
status, age, race and religion. Consequently, gender and pregnancy status that were 
collected in the NTCS were added to the logistic models, whose results are presented in 
the following section.  
 Finally, throughout the results, and in particular when exploring managerial 
attitudes, many interviewees equated methadone with harm reduction (i.e. used the terms 
interchangeably), which they did not view favorably. Mangers believed that using 
methadone is replacing one addiction for another. Views towards 
buprenorphine/naloxone were more accepting. The findings from the interviews suggest 
that the factors influencing the provision of methadone might be different than those 
influencing the provision of buprenorphine/naloxone. Since the NTCS allows for a 
comparison of methadone and buprenorphine/naloxone provision, an additional logistic 
model was added to this study in order to explore any possible differences. This model is 
presented in the following section and is then compared to the model predicting 
buprenorphine/naloxone adoption. 
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Quantitative Findings 
 Descriptive statistics of the variables of interest are presented in tables 6.1 (for the 
dependent variables), 6.2 (for independent dichotomous or categorical variables) and 6.3 
(for independent continuous variables). Methadone was not originally conceptualized as a 
separate dependent variable but is presented in table 6.1 because (1) it was used to 
compute medication-assisted treatment, and (2) the qualitative interviews suggested that 
views towards methadone and buprenorphine/naloxone and the factors influencing their 
adoption might be different. Consequently, logistic models were added to explore the 
factors influencing provision of methadone. 
 Table 6.1 demonstrates that over 90 percent of the centers participating in the 
survey indicated they treat patients who are addicted to opiates (369 centers out of a total 
of 405 centers). Of these 369 centers that treat patients addicted to opiates, only 65 
(17.6%) currently use methadone to treat their clients, and 42 (11.4%) were early 
adopters of buprenorphine/naloxone. However, there was almost no overlap between 
centers currently providing methadone and those providing buprenorphine/naloxone. 
Only four of the centers provided both medications, leading to 103 centers that provided 
at least one medication-assisted treatment option (27.9%). 
 
Table 6.1  
Descriptive Statistics for Dependent Variables (N=369) 
Variable N % 
Currently provide MAT (methadone or 
buprenorphine/naloxone) 
103 27.9 
Currently treat with methadone 65 17.6 
Currently treat with buprenorphine/naloxone 42 11.4 
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 Table 6.2 presents descriptive statistics for independent variables that are 
categorical. The vast majority of private centers in the study had state licensing (94%). 
Over 60% reported being accredited by JCAHO, and 12.6% reported being accredited by 
CARF. About one third of centers reported being owned by a hospital. About 40% 
reported participating in research, and nearly the same amount of centers reported using 
the ASI during intake. Over 7% of centers reported using ASAM criteria to match their 
clients with the appropriate level of care. Finally, almost 40% reported having an active 
alumni program. 
 
Table 6.2  
Descriptive Statistics for Categorical Independent Variables 
Variable N %  
State licensing (coercive) 346 94 
JCAHO accreditation (coercive) 226 61.9 
CARF accreditation (coercive) 46 12.6 
Parent organization medical facility (coercive) 127 34.4 
Participation in research – ever (milieus) 143 39.3 
Use of ASAM to match client with appropriate level of care (milieus) 284 77.6 
Use of ASI during intake (milieus) 139 38 
Active alumni program (milieus) 144 39.2 
 
Table 6.3 presents descriptive statistics for independent variables that are 
continuous. Centers reported that an average 19% of funding came from managed care 
arrangements and that the average impact managed care arrangements was 2.86 (from a 
scale of 0-5). On average, 47% of clients had a dual diagnosis, 54% had relapsed in the 
past, 20% had a primary diagnosis of opiate abuse or dependence, 38% were women and 
4% of the women were pregnant. The average proportion of counselors at a center 
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holding a masters degree or higher was about 40% as was the average proportion of 
counselors in recovery. Directors reported being employed at the center for an average of 
13.1 years and in the behavioral health field for 19.3 years. The average organizational 
age was 23.6 years, and the average size was 68.9 (number of admissions/number of full 
time employees). The average center’s orientation to the medical model was 3.51, 
average knowledge of CTN 0.83, average alumni activity 0.77 (all on a scale of 0-5). 
Finally, centers reported and average of 0.69 on 4 questions designed to measure their 
orientation to the 12-step model.  
 
Table 6.3  
Descriptive Statistics for Continuous Independent Variables 
Variable Mean SD Min Max 
Prop of MC funding (coercive) 0.19 0.25 0 0.99 
Impact of managed care arrangements (mean of 17 items 
on a scale of 0-5 each)(coercive) 
2.86 0.82 0 4.6 
Orientation to medical/psychiatric model of addiction (0-
5)(identity logics) 
3.51 1.76 0 5 
Prop of clients with dual diagnosis (normative) 0.47 0.25  0.01 1 
Prop of clients who are relapsers (normative) 0.54 0.24 0.03 1 
Prop of clients with primary diagnosis of opiate 
dependence or abuse (normative) 
0.2 0.2 0 1 
Prop of counselors – MA level or higher (identity logics) 0.40 0.27 0 0.97 
Prop of counselors in recovery (identity logics) 0.39 0.25 0 0.92 
Knowledge of CTN (0-5) (milieus) 0.83 1.50 0 5 
Alumni activity (mean of 6 items on a scale of 0-5 each) 
(milieus) 
0.77 1.12 0 4.83 
Manager tenure at organization (years) (embedded 
agency) 
13.31 7.12 1 33 
Manager tenure in BH field (embedded agency) 19.33 7.58 1 40 
Age of organization (embedded agency) 23.56 14.07 1 103 
Facility size (# of admissions/FTE's) (embedded agency) 68.89 181.87 1.04 2068. 33 
12-step orientation (mean summary of yes responses to 4 
questions) (identity logics) 
0.69 0.30 0 1 
Prop of clients who are women (normative) 0.38 0.16 0 1 
Prop of women clients who are pregnant (normative) 0.04 0.09 0 0.99 
 
	  89	  	  
 Two logistic regressions models will regress medication-assisted treatment and 
early adoption of buprenorphine/naloxone on the 5 sets of independent variables, 
coercive, normative, competing identity logics, milieus and embedded agency factors. As 
mentioned above, a third model was added to measure the influence of these factors on 
methadone adoption separately. 
 
Factors associated with provision of medication-assisted treatment  
 Table 6.4 presents results of model 1, regressing provision of medication-assisted 
treatment (methadone or buprenorphine/naloxone) on to all hypothesized predictors. 
JCAHO accreditation, proportion of clients with primary diagnosis of opiate dependence 
or abuse, proportion of clients who are women and past participation in research were all 
significantly associated (at the .05 level) with provision of medication-assisted treatment. 
Table 6.4 also presents a second model, which included only these significant four 
predictors from model 1. All four retained their significance in the second model. In 
model 1, state licensing approached significance with provision of medication-assisted 
treatment at p<0.1, and it was not included in model 2. 
 Coercive institutional forces: Of the coercive institutional variables, only JCAHO 
accreditation was a significant predictor of medication-assisted treatment provision. The 
odds of medication-assisted treatment being provided in an organization were almost four 
times greater in organizations that were accredited by JCAHO (AOR=3.85; 95%CI: 2.05-
7.22).  
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 Normative institutional forces: Two of the normative factors were significant 
predictors of medication-assisted treatment provision. A standard increase in the 
proportion of clients with a primary diagnosis of opiate dependence or abuse and clients 
who are women, increases the odds of medication-assisted treatment being provided by 
48 times (AOR=48.03; 95% CI: 12.36-186.54) and 5.4 times, respectively (AOR=5.44; 
95% CI: 1.00-29.47). Proportion of dually diagnosed clients, relapsers and women who 
were pregnant did not significantly predict provision of medication-assisted treatment. 
 Salience of milieus: Only past organizational participation in research was a 
significant predictor of medication-assisted treatment provision. The odds medication-
assisted treatment being provided in an organization almost doubled in organizations that 
had previously participated in research (AOR=1.97; 95% CI: 1.16-3.33). 
 Finally, none of the competing identity logics or embedded agency variables were 
found to be significant predictors of medication-assisted treatment provision in private 
organizations.  
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Table 6.4  
Predictors of medication-assisted treatment  
 Model 1 (full) Model 2 (only significant variables) 
Variable β (SE) Adjusted odds 
ratio (95% CI) 
β (SE) Adjusted odds 
ratio (95% CI) 
Coercive institutional forces 
State licensing  1.901 (1.107)* 6.695  
(0.763-58.727) 
  
JCAHO 
accreditation  
1.358 (0.427)*** 3.890  
(1.684-8.986) 
1.346 (0.322)*** 3.845  
(2.047-7.224) 
CARF 
accreditation  
0.578 (0.471) 1.782  
(0.708-4.484) 
  
Parent 
organization 
medical facility  
0.323 (0.341) 1.382  
(0.708-2.695) 
  
Prop of MC 
funding  
0.286 (0.636) 1.332  
(0.382-4.637) 
  
Impact of 
managed care 
arrangements  
-0.024 (0.035) .976  
(0.911-1.045) 
  
Normative institutional forces 
Prop of clients 
with dual 
diagnosis  
1.054 (0.915) 2.870  
(0.476-17.315) 
  
Prop of clients 
who are relapsers  
0.967 (0.931) 2.631 
 (0.424-16.321) 
  
Prop of clients 
with primary 
diagnosis of 
opiate 
dependence or 
abuse 
3.974 (0.786)*** 
 
53.207 
(11.389 248.562) 
3.872 (0.268)** 48.026  
(12.364-186.541) 
Prop of clients 
who are women 
2.317 (1.025)** 10.150  
(1.360-75.726) 
1.694 (0.862)** 5.440  
(1.004-29.469) 
Prop of women 
clients who are 
pregnant  
-0.228 (1.431) .796  
(0.048-13.169) 
  
Competing identity logics 
Prop of 
counselors – MA 
level or higher  
-0.626 (0.618) .535  
(0.159-1.800) 
  
Prop of 
counselors in 
recovery  
0.945 (0.677) 2.573  
(0.681-9.716) 
  
Orientation to 
medical/ 
psychiatric model 
of addiction 
0.104 (0.105) 1.109  
(0.902-1.364) 
  
12-step 
orientation  
-0.150 (0.604) .861  
(0.264-2.811) 
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 Model 1 (full) Model 2 (only significant variables) 
Variable β (SE) Adjusted odds 
ratio (95% CI) 
β (SE) Adjusted odds 
ratio (95% CI) 
Salience of milieus 
Participation in 
research – ever  
0.646 (0.319)** 1.909  
(1.021-3.568) 
0.677 (0.322)** 1.969  
(1.1647-3.331) 
Knowledge of 
CTN  
0.045 (0.202) 1.046  
(0.704-1.555) 
  
Use of ASI 
during intake 
0.171 (0.385) 1.187  
(0.558-2.524) 
  
Use of ASAM to 
match client with 
appropriate level 
of care  
0.180 (0.305) 1.197  
(0.658-2.179) 
  
Active alumni 
program  
-0.0767 (0.558) .926  
(0.310-2.767) 
  
Alumni activity  -0.062 (0.248) .940  
(0.578-1.527) 
  
Embedded agency 
Manager tenure 
at organization 
0.107 (0.249) 1.114  
(0.678-1.830) 
  
Manager tenure 
in BH field  
-0.012 (0.025) .988 
 (0.942-1.037) 
  
Age of 
organization  
0.054 (0.123) 1.055 
 (0.829-1.344) 
  
Facility size  0.069 (0.160) 1.072 
 (0.782- 1.469) 
  
No. of imputations: m=20; *p<0.1; **p<0.05; ***p<0.01 
 
Factors associated with provision of buprenorphine/naloxone  
 Table 6.5 presents results of model 1 regressing provision of 
buprenorphine/naloxone on to all hypothesized predictors. Proportion of managed care 
funding and proportion of clients with a primary diagnosis of opiate dependence or abuse 
were the only two significant variables. They were added to model 2, also presented in 
table 6.6, and retained their significance. Three additional variables - impact of managed 
care arrangements, proportion of counselors with a masters degree or higher and 
orientation to the medical/psychiatric model of addiction - also approached significance 
with adoption of buprenorphine/naloxone at p<0.1 and were not included in model 2.  
 Coercive institutional forces: Of the coercive institutional variables, only 
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proportion of managed care funding was a significant predictor of adoption of 
buprenorphine/naloxone as a new treatment modality. A standard increase in the 
proportion of clients of managed care funding, increases the odds of 
buprenorphine/naloxone provision by 10.6 times (AOR=10.58; 95% CI: 3.13-35.76), 
suggesting that managed care funding may be freeing up resources that enable 
buprenorphine/naloxone adoption. The impact of managed care arrangements only 
approached significance in the first model at p<0.1, and was therefore not included in 
model 2. 
 Normative institutional forces: Only proportion of clients with a primary 
diagnosis of opiate dependence or abuse was significantly associated with provision of 
buprenorphine/naloxone. A standard increase in the proportion of clients with a primary 
diagnosis of opiate dependence or abuse, increases the odds of buprenorphine/naloxone 
provision by 712% (AOR=7.13; 95% CI: 1.49-34.0). Proportion of dually diagnosed 
clients, relapsers, women and women who were pregnant did not significantly predict 
provision of buprenorphine/naloxone. 
 Finally, none of the competing identity logic, salience of milieus or embedded 
agency variables were found to be significant predictors of early adoption of 
buprenorphine/naloxone in private organizations. However, two of the competing identity 
logics factors – proportion of counselors with a masters degree or higher and the 
organizations’ orientation to the medical/psychiatric model of addiction – approached 
significance in model 1, suggesting they might have a positive effect on provision of 
buprenorphine/naloxone. 
	  94	  	  
Table 6.5  
Predictors of early adoption of buprenorphine/naloxone  
 Model 1 (full) Model 2 (only significant variables) 
Variable β (SE)  Adjusted odds 
ratio (95% CI) 
β (SE) Adjusted odds 
ratio (95% CI) 
Coercive institutional forces 
State licensing  0.284 (1.159) 1.329  
(0.137- 12.911) 
  
JCAHO 
accreditation  
0.237 (0.561) 1.267  
(0.422-3.802) 
  
CARF 
accreditation  
0.049 (0.657) 1.050  
(0.290-3.805) 
  
Parent 
organization 
medical facility  
-0.12 (0.469) .887 
(0.354-2.222) 
  
Prop of MC 
funding  
2.078 (0.803)*** 7.990 
(1.651-38.681) 
2.359 (0.621)*** 10.579 
(3.129-35.764) 
Impact of 
managed care 
arrangements  
-0.088 (0.051)* .916 
(0.828-1.013) 
  
Normative institutional forces 
Prop of clients 
with dual 
diagnosis  
0.765 (1.387) 2.149 
(0.139-33.106) 
  
Prop of clients 
who are relapsers  
0.574 (1.301) 1.776 
(0.139-22.762) 
  
Prop of clients 
with primary 
diagnosis of 
opiate 
dependence or 
abuse 
2.189 (1.021)** 8.926 
(1.206-66.047) 
1.964 (0.797)** 7.126 
(1.493-34.002) 
Prop of clients 
who are women 
0.925 (1.403) 2.522 
(0.161-39.442) 
  
Prop of women 
clients who are 
pregnant  
-1.018 (2.362) .361 
(0.004-37.064) 
  
Competing identity logics 
Prop of 
counselors – MA 
level or higher  
1.604 (0.900)* 4.973 
(0.849-29.136) 
   
Prop of 
counselors in 
recovery  
0.131 (0.986) 1.140 
(0.164-7.920) 
  
Orientation to 
medical/ 
psychiatric model 
of addiction 
1.159 (0.884)* 1.268 
(0.940-1.712) 
 
  
12-step 
orientation  
0.542 (0.852) 1.720 
(0.323-9.143) 
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 Model 1 (full) Model 2 (only significant variables) 
Variable β (SE)  Adjusted odds 
ratio (95% CI) 
β (SE) Adjusted odds 
ratio (95% CI) 
Salience of milieus 
Participation in 
research – ever  
-0.234 (0.446) .791 
(0.330-1.898) 
  
Knowledge of 
CTN  
0.039 (0.263) 1.040 
(0.620-1.743) 
  
Use of ASI 
during intake 
0.412 (0.599) 1.917 
(0.593-6.200) 
  
Use of ASAM to 
match client with 
appropriate level 
of care  
0.651 (0.407) 1.510 
(0.680-3.355) 
  
Active alumni 
program  
-0.104 (0.740) .901 
(0.211-3.844) 
  
Alumni activity  0.382 (0.310) 1.466 
(0.789-2.692) 
  
Embedded agency 
Manager tenure 
at organization 
0.170 (0.324) 1.186 
(0.621-2.263) 
  
Manager tenure 
in BH field  
-0.020 (0.036) .980 
(0.914-1.052) 
  
Age of 
organization  
0.142 (0.159) 1.153 
(0.843-1.577) 
  
Facility size  0.097 (0.202) 1.102 
(0.843-1.577) 
  
No. of imputations: m=20; *p<0.1; **p<0.05; ***p<0.01 
 
Factors associated with provision of methadone  
 Table 6.8 presents results of the model regressing provision of methadone on to 
all hypothesized predictors. JCAHO accreditation, proportion of clients with a primary 
diagnosis of opiate abuse or dependence and women, proportion of counselors with a 
masters degree or higher and past participation in research were all significantly 
associated with methadone provision at p<0.05. These five variables were retained for 
model 2 and all retained their significance. Several other variables were significant at 
p<0.1 - CARF accreditation, impact of managed care arrangements, proportion of clients 
who are dual diagnosis and use of ASI during intake – and were not included in model 2. 
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 Coercive institutional forces: Similar to the medication-assisted treatment model, 
only JCAHO accreditation was a significant predictor of methadone provision. The odds 
of methadone being provided in an organization were almost 6 times greater in 
organizations that were accredited by JCAHO (AOR=5.94; 95% CI=2.5-14.1). Two 
additional coercive factors - CARF accreditation and impact of managed care 
arrangements - approached significance in the first model, and were not included in 
model 2. The latter also approached significance in the model predicting 
buprenorphine/naloxone adoption, though in the opposite direction  
 Normative institutional forces: Again, similar to the medication-assisted treatment 
model, two of the normative factors were significant predictors of methadone provision. 
A standard increase in the proportion of clients with a primary diagnosis of opiate 
dependence or abuse and clients who are women, increases the odds of medication-
assisted treatment being provided by 55 times (AOR=55.05; 95% CI: 11.28-268.68) and 
14 times, respectively (AOR=14.35; 95% CI: 1.86-110.67). Proportion of dually 
diagnosed clients approached significance, while relapsers and women who were 
pregnant did not significantly predict provision of methadone, though. 
 Competing identity logics: This was the only model in which an identity logics 
factor was found to be significant. Interestingly, the effect was negative. For every 
standard unit increase in the proportion of counselors with a master’s degree or higher, 
the likelihood of offering methadone decreased by 81% (AOR=0.19; 95% CI: 0.05-0.63). 
 Salience of milieus: Once again, similar to the medication-assisted treatment 
model, only past organizational participation in research was a significant predictor of 
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methadone provision. The odds of methadone being provided in an organization nearly 
tripled in organizations that had previously participated in research (AOR=2.8; 95% CI: 
1.47-5.31). Use of ASI during intake approached significance (p<0.1) and was not 
included in the final model 
 Finally, similar to both previous models, none of the embedded agency variables 
were found to be significant predictors on methadone provision in private organizations.  
   
Table 6.6  
Predictors of methadone adoption  
 Model 1 (full) Model 2 (only significant variables) 
Variable β (SE)  Adjusted odds 
ratio (95% CI) 
β (SE) Adjusted odds 
ratio (95% CI) 
Coercive institutional forces 
JCAHO 
accreditation  
2.444 (0.738)*** 10.283 
(3.190-33.141) 
1.782 (0.441)*** 5.942 
(2.504-14.103) 
CARF 
accreditation  
1.353 (0.744)* 2.142 
(0.622-6.930) 
  
Parent 
organization 
medical facility  
0.513 (0.483) 1.352 
(0.569-3.069) 
  
Prop of MC 
funding  
-1.489 (1.289) 0.162 
(0.022-1.175) 
  
Impact of 
managed care 
arrangements  
0.089 (0.053)* 1.038 
(0.951-1.133) 
  
Normative institutional forces 
Prop of clients 
with dual 
diagnosis  
2.495 (1.477)* 3.765 
(0.349-40.599) 
  
Prop of clients 
who are relapsers  
1.571 (1.386) 4.386 
(0.433-44.436) 
  
Prop of clients 
with primary 
diagnosis of 
opiate 
dependence or 
abuse 
5.242 (1.123)*** 69.649 
(11.269-430-489) 
4.008 (0.806)*** 55.046 
(11.277-268.684) 
Prop of clients 
who are women 
3.876 (1.577)** 16.506 
(1.225-222.365) 
2.664 (1.042)** 14.350 
(1.860-110.669) 
 
Prop of women -0.714 (2.035) 1.642   
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 Model 1 (full) Model 2 (only significant variables) 
Variable β (SE)  Adjusted odds 
ratio (95% CI) 
β (SE) Adjusted odds 
ratio (95% CI) 
clients who are 
pregnant  
(0.074-36.531) 
Competing identity logics 
Prop of 
counselors – MA 
level or higher  
-2.017 (0.883)** 0.117 
(0.026-0.514) 
-1.686 
(0.625)*** 
0.185  
(0.054-0.631) 
Prop of 
counselors in 
recovery  
0.660 (1.042) 1.717 
(0.331-8.911) 
  
Orientation to 
medical/ 
psychiatric model 
of addiction 
0.019 (0.157) 0.971 
(0.751-1.256) 
  
12-step 
orientation  
-1.265 (0.910) 0.353 
(0.084-1.494) 
  
Salience of milieus 
Participation in 
research – ever  
1.113 (0.491)** 3.300 
(1.462-7.451) 
1.029 (0.323)*** 2.798 
(1.474-5.310) 
Knowledge of 
CTN  
0.154 (0.312) 1.097 
(0.655-1.836) 
  
Use of ASI 
during intake 
-0.956 (0.579)* 0.832 
(0.3434-2.071) 
  
Use of ASAM to 
match client with 
appropriate level 
of care  
-0.103 (0.464) 1.233 
(0.579-2.625) 
  
Active alumni 
program  
-0.326 (0.872) 1.370 
(-.328-5.719) 
  
Alumni activity  -0.438 (0.427) 0.995 
(0.270-1.118) 
  
Embedded agency 
Manager tenure 
at organization 
0.025 (0.373) 1.037 
(0.547- 1.966) 
  
Manager tenure 
in BH field  
0.008 (0.549) .995 
(0.936-1.059) 
  
Age of 
organization  
-0.064 (0.182) 0.924 
(0.677-1.261) 
  
Facility size  -0.048 (0.255) 1.049 
(0.712-1.546) 
  
No. of imputations: m=20; *p<0.1; **p<0.05; ***p<0.01 
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Summary 
 Table 6.7 summarizes only the significant variables from all the models and their 
direction. According to the table there are many independent variables (including all of 
the embedded agency variables) that do not significantly predict any of the dependent 
variables that were explored. However, several of the variables significantly predict more 
than one variable.  
 Coercive institutional forces: JCAHO accreditation was a significant predictor of 
both medication-assisted treatment provision and methadone provision separately, but not 
of buprenorphine/naloxone adoption. Proportion of managed care funding, on the other 
hand, was a significant predictor of buprenorphine/naloxone adoption but not of 
medication-assisted treatment and methadone provision. Impact of managed care 
arrangements approached significance in both the buprenorphine/naloxone and 
methadone models, though in the opposite direction. State licensing approached 
significance only in the medication-assisted treatment model, while CARF accreditation 
approached significance only in the methadone model. Having a medical facility as a 
parent organization was not significant in any of the models. 
 Normative institutional forces: As expected, proportion of clients with a primary 
diagnosis of opiate dependence or abuse positively predicted all three dependent 
variables. Proportion of women clients, a variable added to the analysis following the 
qualitative interviews, was a significant predictor of both medication-assisted treatment 
provision and methadone provision separately. This finding supported the theme brought 
up by several of the interviewees. Proportion of clients with dual-diagnosis approached 
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significance only in the methadone model, while proportion of relapsers and pregnant 
women was not significant in any of the models. 
 Competing identity logics: Proportion of counselors with a master’s degree or 
higher was a significant negative predictor in the methadone provision model and 
approached significance in the opposite direction in the buprenorphine/naloxone model. 
Orientation to the medical/psychiatric model of addiction approached significance in the 
buprenorphine/naloxone model but not the other two models, while proportion of 
counselors in recovery and orientation to 12-step ideology were not significant in any of 
the models. 
 Salience of milieus: Only past organizational participation in research was a 
significant predictor of medication-assisted treatment provision, as well as of methadone 
provision separately. Use of ASI during intake approached significance in the model 
predicting methadone provision, while use of ASAM, knowledge of CTN, having an 
active alumni program and the level of alumni activity were not significant predictors in 
any of the models. 
 Embedded agency: None of the embedded agency variables were found to be 
significant predictors of any of the dependent variables.  
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Table 6.7. 
Significant associations of hypothesized predictors 
 
Variable Medication-assisted 
treatment 
Buprenorphine/
naloxone 
Methadone 
Coercive institutional forces 
State licensing  (+)    
JCAHO accreditation  +  + 
CARF accreditation    (+)  
Parent organization medical facility     
Prop of MC funding   +  
Impact of managed care arrangements   (-) (+)  
Normative institutional forces 
Prop of clients with dual diagnosis    (+)  
Prop of clients who are relapsers     
Prop of clients with primary diagnosis 
of opiate dependence or abuse 
+ + + 
Prop of clients who are women +  + 
Prop of women clients who are 
pregnant  
   
Competing identity logics 
Prop of counselors – MA level or 
higher  
 (+)  - 
Prop of counselors in recovery     
Orientation to medical/psychiatric 
model of addiction 
 (+)  
12-step orientation     
Salience of milieus  
Participation in research – ever  +  + 
Use of ASAM to match client with 
appropriate level of care  
   
Use of ASI during intake   (+) 
Knowledge of CTN     
Active alumni program     
Alumni activity     
Embedded agency 
Manager tenure at organization    
Manager tenure in BH field     
Age of organization     
Facility size     
*(-) or (+) indicate the variable approached significance in model 1 at p<0.1 and was not subsequently 
included in model 2. 
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Chapter 7 
Summary and Discussion 
 Despite the demonstrated effectiveness of both methadone and 
buprenorphine/naloxone in the treatment of opioid dependence, only 17.5 percent of 
private treatment facilities offer methadone to their clients, while a little over 10% offer 
buprenorphine/naloxone. Interestingly, only four centers provided both medications. 
Previous studies, conducted within NIDA’s Clinical Trails Network (CTN), indicated that 
the odds of buprenorphine/naloxone adoption were significantly greater in programs 
offering methadone (Knudsen et al., 2009; Koch, Arfken, & Schuster, 2006). However, 
this was not sustained at a 24-month follow-up when the availability of methadone was 
no longer associated with buprenorphine/naloxone adoption (Knudsen et al., 2009), 
suggesting that while provision of medication-assisted treatment in general was low, 
buprenorphine/naloxone was adopted by organizations that did not previously offer 
pharmacotherapies.    
 Neoinstitutional forces, as well as institutional logics influence provision of 
medication-assisted treatment in substance abuse treatment facilities. Several factors 
emerged as significant predictors of the dependent variables. Only one factor, the 
proportion of clients with a primary diagnosis of opiate dependence, was positively 
associated with all dependent variables. Predictors for medication-assisted treatment were 
very similar to those of methadone alone; all four factors associated positively with 
mediation-assisted treatment in general were also positively associated with methadone 
separately. It is important to keep in mind that medication-assisted treatment was 
	  103	  	  
comprised only of methadone and buprenorphine/naloxone, and that more facilities 
provided methadone. However, predictors of methadone provision were not similar to 
those for the early adoption of buprenorphine/naloxone.  
 Coercive institutional forces: Both qualitative and quantitative results indicate 
that coercive forces, such as managed care and accreditation, play a role in the provision 
of medication-assisted treatment. 
 Managed care: The proportion of managed care funding was a positive 
significant predictor of early adoption of buprenorphine/naloxone. Scholars have found 
how managed care’s propensity to curtail costs has resulted in the reduction of service 
provision, mostly in public facilities. Managed care regulation was negatively correlated 
with treatment intensity (Lemak & Alexander, 2001) and the number of services provided 
(Corcoran & Vandiver, 1996; Gold, Hurley, Lake, Ensor & Berenson, 1995; Olmstead, 
White & Sindelar, 2004). It was also found to limit autonomy of the provider (Alexander 
& Lemak, 1997; Mechanic, Schlesinger, & McAlpine, 1995; Schlesinger, Dorward, & 
Epstein, 1996; Schwartz & Wetzler, 1998), not increase technical efficiency in service 
provision (Alexander, Wheeler, Nahra & Lemak, 1998) and increase relapse rates (Sosin, 
2005).  
 However, the findings in this study suggest that the availability of managed care 
funds promotes evidence-based innovation, which is supported by recent literature. 
Roman and Johnson (2002) found that early adoption of naltrexone was positively and 
significantly associated with the percentage of the center's caseload covered by managed 
care programs. Also, in their study of early adoption of buprenorphine/naloxone, 
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Knudsen and colleagues (2006) found that private centers were significantly more likely 
than public centers to report current use of buprenorphine/naloxone. It is possible that 
managed care is more sympathetic to innovative interventions like 
buprenorphine/naloxone because there is data to show that it will translate to better 
results in efficient private care settings, thus curtailing costs in the long run.  
Managed care firms have the option is to deny care (or various aspects of care), and they 
may be authorizing certain types of clients and treatment options over others. 
Interestingly, the impact of managed care arrangements (how involved they are in 
organizational decision-making processes) approached significance in the first model, 
suggesting a possible opposite effect on buprenorphine/naloxone provision. It is possible 
that in organizations where managed care is more involved in day-to-day operations, 
adoption becomes increasingly challenging. Future research needs to examine possible 
differential beliefs about private versus public facilities and medication-assisted treatment 
on the part of managed care funders. 
 Accreditation: In the qualitative interviews accreditation was mostly viewed as a 
hindrance, as regulatory agencies sometimes force agencies to take measures and provide 
services that are not in line with the current norms of the organizations or the treatment 
modality. The quantitative results showed that JACHO accreditation significantly 
associated with both medication-assisted treatment provision and methadone provision 
separately, though not of early adoption of buprenorphine/naloxone. It is important to 
note here again that organizations who provide methadone, must be licensed to do to. The 
same is not true for buprenorphine/naloxone which is less tightly controlled and can be 
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prescribed by many qualified doctors in primary care settings. These findings are only 
partially consistent with previous research, which found that accreditation increases 
service provision of HIV services to seropositive clients (Ghose, 2006) as well as early 
adoption of buprenorphine/naloxone (Knudsen et al., 2006). However, it lends support to 
the hypothesis emerging from the qualitative interviews that the factors influencing 
adoption of each drug are not the same; while funding is essential for early adoption of 
buprenorphine/naloxone, accreditation may be a more salient factor in the provision of 
methadone. 
 Normative institutional forces: The salience of client characteristics in 
influencing adoption and provision of services was supported by both the qualitative and 
quantitative findings. Managers provided multiple detailed examples of how 
organizations adapt and change to cater to the needs of certain types of clients. One of the 
main themes discussed was how treating opiate-addicted women, particularly pregnant 
women, forces the organization to be more open to providing methadone (or referring to 
organization who already provide methadone). Subsequently, the proportion of women 
treated by the organization was added to the logistic analysis. Though this variable has 
not previously been explored, it emerged as a significant predictor of both medication-
assisted treatment provision and methadone provision, but not of 
buprenorphine/naloxone. 
 As expected, proportion of clients with a primary diagnosis of opiate dependence 
or abuse positively predicted all three dependent variables. This is consistent with 
previous research (Ghose, 2006; Knudsen et al., 2006), and lends further support to the 
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hypothesis that clients, who comprise the ‘raw material’ of human service organizations, 
dictate the types of treatment and service technologies adopted by the organization 
(Hasenfeld, 1992). Organizational theorists have noted that institutional norms, standards 
and expectations shape and structure processes (Barley & Tolbert, 1997; Cooney, 2007; 
Orlikowski, 2000). Organizations and institutions thus both constrain agency, ideology 
and materials but are also subject to them (Giddens, 1984; Sewell, 1992). 	   
 Competing identity logics: Managers often described ideological clashes within 
the substance abuse treatment field. Many traced the source of these clashes to the 
merging of the substance abuse and mental health fields. Similar to work by D’Aunno 
and colleagues (1991), managers discussed how people in the field are subject to two 
beliefs systems, or sets of ideological logics, which are often at odds. They argued that 
that people coming from the substance abuse treatment field are more traditional and 
more likely to adhere to the 12-step/abstinence/AA model of addiction, often as a result 
of their personal experience with substance abuse, while people coming from the mental 
health field hold a more medical orientation towards addiction and are often more 
educated. Though not mutually exclusive, is was suggested that those with a background 
in mental health education favor the use of medication-assisted treatment, while those 
with a substance abuse background prefer total abstinence from all substances, 
methadone included. However, when buprenorphine/naloxone was discussed, it was 
viewed as a short-term crutch, and more acceptable than methadone among those who 
identified themselves as belonging to the ‘old-school’ model.  
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 Interestingly, the logistic analysis painted a slightly different picture. The 
proportion of counselors with a master’s degree or higher was a significant negative 
predictor in the methadone provision model and only approached significance in the 
positive direction in the buprenorphine/naloxone model. A possible explanation for these 
finding is that people with higher education have better access to and knowledge of 
research on innovative approaches to treatment. Therefore, they may have been aware of 
the new medication available, buprenorphine/naloxone, and supportive of introducing it 
as a treatment option, perhaps even offering it instead of the already available alternative, 
methadone.   
 As previously mentioned, many of the managers who were interviewed expressed 
differential orientations towards methadone and buprenorphine/naloxone. While 
methadone was often viewed as replacing one addictive substance with another, 
buprenorphine/naloxone was viewed as an innovative medication for the treatment of 
addiction. Furthermore, ‘methadone’ was often used interchangeably with ‘harm 
reduction’, which was not viewed favorably by many managers. Scholarship indicates 
that methadone maintenance is often considered a controversial issue (McLellan, 2003) 
and can be considered a harm reduction strategy (Weschberg & Kasten, 2007).  
Riley and O’hare (2000) summarized some of the main barriers to harm reduction 
practices. The main argument is that people who would not otherwise use drugs might 
begin doing so if they perceive that it is safe and legal (or at the least not criminalized). 
They also argued that currently society does not accept drug use as a ‘legitimate form of 
risk taking’, thus the moral stance is prevalent. These notions, in addition to laws already 
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in place and to lack of knowledge in the general public regarding the true nature of 
substance abuse, leads to a political climate which is less than supportive of efforts to 
implement harm reduction measures (Riley & O’Hare, 2000), possibly including 
methadone. At the organizational level, Rosenberg and Phillips (2003) that the low rates 
of adoption of methadone, which were conceptualized as a form of harm reduction in 
their study, were attributed mostly to lack of consistency with agency philosophy, and to 
a lesser degree, to a lack of resources and funding. Buprenorphine/naloxone was not 
included in their study as a form of harm reduction, also supporting the need to 
distinguish between the two substances, in research and in practice. Future research 
should explore trends in the adoption as well as discontinuation of the two substances. 
This finding, though surprising, lends additional support to the merit of exploring 
methadone and buprenorphine/naloxone adoption separately.  
 Salience of milieus: Research has called for the examination of the role of 
networks and interorganizational relationships in influencing medication adoption 
(Ducharme et al. 2007). Findings from the qualitative interviews indicate that research 
networks are important in promoting adoption. Access and participation in research and 
training were viewed as critical in the process of adopting new practices and in 
determining service provision. However, knowledge of evidence-based practice was not 
enough. Many stressed that in order for their organization to provide a service or consider 
adding an innovation to their menu of available treatment options, it must be consistent 
with the organizational philosophy.  
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 The logistic analysis also indicated that research networks have a role in service 
provision. Past organizational participation in research was a significant predictor of 
medication-assisted treatment provision, as well as of methadone separately. Though 
further research in this area is needed, previous literature has found that units whose 
directors were linked to external professional networks were more likely to provide HIV 
prevention, have collaborative relationships with other agencies and survive over time 
(D’Aunno, 2006). Knudsen and colleagues (2009) also linked the adoption of 
buprenorphine/naloxone to involvement in a buprenorphine/naloxone protocol. This in 
turn, carries with it significant policy and practice implications.  
 Embedded agency: None of the embedded agency variables were found to be 
significant predictors of any of the dependent variables. In previous research, 
organizational size in particular, has been consistently found to be a positive predictor of 
medication adoption in general and buprenorphine/naloxone adoption in particular 
(Knudsen et al., 2006, 2007a; Duchrame & Roman, 2009). Two possible explanations are 
offered for the lack of statistical significance of these factors in predicting the dependent 
variables. First, the data set used in this study only captures the universe of private 
treatment facilities, and it is likely that organizational characteristics such as age and size 
will emerge as significant predictors of medication-assisted treatment when exploring the 
whole universe of substance abuse treatment facilities. Second, it is possible that the 
operationalization of embedded agency (size and age for the organization and tenure for 
managers) did not capture the complexity of the idea that individuals and organizations 
may be influencing their institutional environment.  
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 In sum, the multiple factors discussed by decision-makers, support the use of a 
comprehensive conceptual framework to study adoption of practices, particularly in a 
field that is as fragmented and value-laden as substance abuse treatment. The large, 
nationally representative data set used for this study, combined with multiple imputation 
procedures to handle missing data, allowed for inclusion of multiple predictors in the 
analysis, thereby addressing one limitation of previous research (e.g. as suggested by 
Knudsen et al., 2009). 
Implications for organizations: 
 The results of this study have several implications for substance abuse treatment 
organizations:  
 Managed care funding was positively associated with early adoption of 
buprenorphine/naloxone, suggesting that managed care encourages early adoption of 
innovation. This suggests that managed care views buprenorphine/naloxone as a 
medication and is therefore more likely to fund it. This point carries with it important 
implications for managers who need to make decisions on how to fund treatment for 
clients. Decision makers in private facilities looking to add a medication to their regime, 
should be aware that buprenorphine/naloxone might be an easy sell to managed care; the 
goal of managed care firms is to save money, and buprenorphine/naloxone is a cheaper 
treatment avenue than residential care or detoxification for clients suffering from opioid 
dependence. With this in mind, managed care arrangements and their involvement in 
organizational professional decision-making processes should be carefully reviewed, and 
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further research is a needed in this area, particularly research exploring how managed 
care funders view different medication-assisted treatments. 
 Organizations encounter different types of clients and they must cater their 
services to meet clients’ unique needs. This requires specialized training oriented towards 
innovations and evidence-based practices. For instance, working with opiate addicts 
requires training on available medications for opiate addiction. Having managers attend 
research conventions, fostering research connections with universities and research 
centers and participating in research can, at the very least, orient managers to innovations 
in the field, thereby adding to their knowledge and perhaps shaping attitudes towards 
treatment options that are more controversial.  
Implications for policy: 
Several implications for policy also arise from this study: 
 Accreditation by JCAHO was positively associated with adoption of medication-
assisted treatment. However, there are still large portions of private facilities that are not 
licensed by JCAHO, suggesting there is room for growth in this area. This implication is 
supported by findings of previous research, which found that facilities accredited by 
JCAHO were more likely to provide primary care and mental health services (Friedmann 
et al., 1999; D’Aunno, 2006), physical exams and routine medical care (Durkin, 2002), 
use antidepressants (Knudsen et al., 2007b) and be early adopters of 
buprenorphine/naloxone (Knudsen et al, 2006). It is important to note that this is a cross-
sectional survey, and therefore it is also possible that the adoption of practices predates 
organizational accreditation. However, as accreditation has consistently been shown to 
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promote service provision, organizational efforts to gain accreditation should be 
supported. Furthermore, licensing and accreditation agencies can monitor training and 
research efforts to help organizations achieve better outcomes and increase their 
efficiency.     
 Being involved in research milieus facilitates the uptake of innovative 
medication-assisted treatment. Organizations should also aspire to increase their 
participation in research, and managers should be made part of academic-provider 
partnerships - such as has been done by the National Institute on Drug Abuse (NIDA) in 
their Clinical Trial Network (CTN) program. Though this involvement may not 
necessarily encourage managers to become more positively disposed towards certain 
controversial evidence-based practice (methadone), the results of this research indicate 
that being involved in research networks makes them more likely to adopt others 
(buprenorphine/naloxone). Furthermore, involvement in these networks can help 
organizations shift to outcome oriented thinking. A focus on outcomes, which are 
directed towards the unique, needs of clients, can in turn help promote better quality of 
care, and is in line with the increasing demands for transparency and accountability in 
human service organizations in general and substance abuse treatment organizations in 
particular, shrinking social service budgets and increased commitment to improved 
services and results-oriented management. (McLellan, Carise, & Kleber, 2003; McLellan, 
Chalk, & Bartlett, 2007; McLellan, Kemp, & Brooks, 2008; McLellan, McKay, Forman, 
Cacciola, & Kemp, 2005).  
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Utility of conceptual model 
 The use of theory in the study of substance abuse treatment is limited. With the 
notable exception of D’Aunno and colleagues (D’Aunno et al., 1991; D’Aunno et al, 
1999), and very recent work by Roman and colleagues (Savage et al., 2012) most 
scholars do not employ a comprehensive conceptual framework to identify organizational 
predictors, or to interpret results. As a result, research on organizational research in 
substance abuse treatment has tended to focus on top-down institutional forces shaping 
treatment. 
 Utilizing a comprehensive framework, such as the one in this study, allows for 
organization of the institutional, organizational and individual forces at play in decisions 
regarding service provision. Moreover, it allows for exploring certain variables that have 
not been highlighted in previous research that may be salient. The conceptual framework 
can help highlight important dynamics that are taking place in the field. For example, the 
salience of research milieus was predicted by the conceptual model, yet is not often 
included as a factor of interest in organizational studies in the field. The importance of 
institutional logics and of individuals embedded in organizations to facilitate 
organizational change is another example, a theme highlighted in the qualitative results. 
 The conceptual model may also be utilized to explain anomalous results. For 
instance, while managed care has often been found to undermine service provision in 
previous research, was beneficial for the adoption of buprenorphine/naloxone in this 
research. Use of the conceptual model allows us to theorize regarding possible 
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explanations, such as how the influence of coercive forces aligns with the use of efficient 
technology. 
Limitations  
 This study has several limitations. First, While NTCS is a nationally 
representative dataset, rich in organizational and institutional variables it was not 
constructed with a specific conceptual framework in mind or with the goal of testing 
theory. Therefore, measuring concepts such as those discussed here was not ideal. Future 
research needs to address these complex concepts and others by including appropriate 
measures. 
 A second related limitation is that the NTCS included primarily organizational 
variables, and did not account for the possible role of agency. Future research should 
explore the role of individuals within the organization (from different positions and 
professions). As noted by Oliva and colleagues (2011), considerably less attention has 
been paid to research examining patient perspectives, knowledge, and attitudes regarding 
medication-assisted treatment in general and the various medications in particular. 
Additional qualitative work might also be useful in exploring these issues.  
 Third, the NTCS included only private facilities, which were uniquely defined as 
those receiving less than 50% of their annual operating revenues from government grants 
or contracts. It is possible that organizations do not characterize themselves based on this 
criterion. A possible alternative might be to use the actual proportion of public or private 
funding as continuous measures, rather than forcing a dichotomous public/private 
distinction in the current economic environment. Regardless, future research should 
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include the entire universe of facilities, allowing for a comparison of public and private 
facilities when appropriate.  
 The public vs. private comparison has been a major variable of concern in 
previous literature, and previous studies have demonstrated that private centers were 
more likely to be early adopters of buprenorphine/naloxone and provide methadone to 
their clients (Knudsen et al., 2006; Knudsen, Abraham, & Roman, 2011), suggesting that 
the low rates of adoption in private facilities might be even lower for substance abuse 
treatment organizations in general. Furthermore, it is likely that the public/private 
division, which could not be addressed in this study, may interact with some of the 
factors explored in this study, to impact service provision and innovation adoption.  
 Fourth, the available data are cross-sectional and therefore any analysis cannot 
include historical trends or changes. Any analysis yields correlational results and causal 
inferences cannot be made. Future research that utilizes longitudinal data and analysis of 
trends is needed, for instance, in the comparison of adoption and discontinuation of 
methadone compared to buprenorphine/naloxone. 
 Finally, I utilize multiple imputations to account for missing data. Though the 
literature is in agreement that this is one of the preferred methods for dealing with 
missing values in order to keep the sample unbiased and as large as possible (Allison, 
2010; Enders, 2010) it must be noted that two of the variables that were significant in the 
models – proportion of managed care funding and proportion of counselors with a 
masters degree or higher – had a relatively high percentage of missing data (20.9 and 
20.6, respectively). Biased estimations increase as the rates of missing data increase, 
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though accurate estimates were found as long as missingness was up to approximately 
25% (Enders, 2010). 
Suggestions for future research 
 Based on the results of this study, both quantitative and qualitative, several 
additional suggestions for future research are offered. One avenue for future research 
might be to explore harm reduction practices other than methadone to see if findings from 
this study are consistent and if methadone can conceptually be categorized as a harm 
reduction practice.  
 Themes emerging from the qualitative interviews also suggest that future research 
should examine attitudes towards adoption of specific innovations (e.g. attitudes of 
clients, employees, decision-makers), individual and organizational decision-making 
processes, patient preferences, as well as public policy and societal-level barriers to 
adoption.  
 In general, the use of an organizing framework as well as incorporation of 
qualitative methods can help point to additional factors that might be influencing the 
adoption of practices, as was the case with proportion of women in this study. A next 
logical step, would be to design and conduct studies that manipulate these organizational-
level variables to promote adoption of evidence-based practices in general, and 
medication-assisted treatment in particular, with the goal of improving the quality of 
services in the field. The widespread adoption of medication-assisted treatments, new and 
established, requires large-scale organizational changes that can only be achieved through 
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comprehensive and multi-faceted initiatives that take into account all levels of 
organizational life. 
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Appendix 1: Semi-structured qualitative interview  
for managers of substance abuse treatment facilities 
Services 
1) Could you tell us about the type of services offered at this facility? 
2) Follow-up: Could you tell us about the following services at this facility?  
a) Substance use treatment services 
b) Mental health services 
c) Medical services 
d) HIV-related services 
e) Supplemental services (transportation, childcare, housing) 
3) Are there areas that you feel this facility excels in providing services? If you had the 
resources, what type of services would you like to add?  
4) What do you feel about evidence-based practice/services? Do you have ways to link 
research with practice?  
Ideology/Orientation 
5) Could you tell us about your views about how best to treat substance use 
6) Follow-up: Explore disease model vs. harm reduction model. Explore chronic vs 
acute conceptualization of substance use. 
7) Do you think being an ex-user is preferable in a counselor? If so why, if not, why 
not? 
8) What are your views on brief treatment? Outpatient treatment? Residential treatment? 
Methadone maintenance/opioid replacement therapy? Harm reduction vs abstinence? 
9) Can you tell us about venues (meetings, conferences, gatherings) where you meet 
other facility managers, counselors and members of the treatment community in 
Philadelphia?  
10) Follow-ups: Could you tell us about what gets discussed at these venues? What is the 
level of contact you have with fellow members of the treatment community? 
11) In your opinion, how prevalent/popular in the treatment community are views 
supporting: a)Harm reduction, b) abstinence, c) using ex-addicts as counselors, d) 
using licensed professional counselors d) using AA/NA groups, e) using brief 
treatment modalities, f) using methadone maintenance treatment? 
12) How do you find out/keep track about what views are prevalent in the treatment 
community? 
Funding? 
13) What are the funding streams for your facility? What proportion of funds are 
government (explore type of gov funding- Medicaid, managed medicaid etc); client-
paid fees per session; managed care;  
14) Have you seen a change in funding during the last 5-7 years? What are they? How has 
managed care funding affected you?  
Personnel 
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15) What is the size of the staff at your facility? How many counselors? How many 
degreed counselors, paraprofessionals? 
16) What is your opinion about ex-users as counselors? Degreed counselors providing 
treatment? 
17) How does funding influence the personnel you hire?  
Clients 
18) What is the demographic profile of your clients? Do you see more of a certain type of 
clients that others? How do you feel these clients are best treated? 
19) Does funding affect the types of clients the facility treats? How do you retain clients 
who need more long-term care in the present funding environment? 
 
  
 
 
 
